

International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names: List 69

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Lists of Proposed (1–105) and Recommended (1–66) International Nonproprietary Names can be found in *Cumulative List No. 14, 2011* (available in CD-ROM only).

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES: Liste 69

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9); résolution EB115.R4 (EB115/2005/REC/1)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.

On trouvera d'autres listes de Dénominations communes internationales proposées (1–105) et recommandées (1–66) dans la *Liste récapitulative No. 14, 2011* (disponible sur CD-ROM seulement).

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS: Lista 69

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9); Resolución EB115.R4 (EB115/2005/REC/1) EB115.R4 (EB115/2005/REC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.

Las listas de Denominaciones Comunes Internacionales Propuestas (1–105) y Recomendadas (1–66) se encuentran reunidas en *Cumulative List No. 14, 2011* (disponible sólo en CD-ROM).

Latin, English, French, Spanish:
Recommended INN

Chemical name or description; Molecular formula; Graphic formula

DCI Recommandée

Nom chimique ou description; Formule brute; Formule développée

DCI Recomendada

Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada

actoxumabum

actoxumab

immunoglobulin G1-kappa, anti-(*Clostridium difficile* toxin A), *Homo sapiens* monoclonal antibody;
gamma1 heavy chain (1-449) [*Homo sapiens* VH (IGHV5-51*01 (94.90%) -(IGHD)-IGHJ3*02) [8.8.12] (1-119) -IGHG1*03 (120-449)], (222-215')-disulfide with kappa light chain (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (100.00%) -IGKJ1*01) [7.3.9] (1'-108') -IGKC*01 (109'-215')]; (228-228":231-231")-bisdisulfide dimer

actoxumab

immunoglobuline G1-kappa, anti-(*Clostridium difficile* toxine A), *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma1 (1-449) [*Homo sapiens* VH (IGHV5-51*01 (94.90%) -(IGHD)-IGHJ3*02) [8.8.12] (1-119) -IGHG1*03 (120-449)], (222-215')-disulfure avec la chaîne légère kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (100.00%) -IGKJ1*01) [7.3.9] (1'-108') -IGKC*01 (109'-215')]; dimère (228-228":231-231")-bisdisulfure

actoxumab

immunoglobulina G1-kappa, anti-(toxina A de *Clostridium difficile*), anticuerpo monoclonal de *Homo sapiens* ;
cadena pesada gamma1 (1-449) [*Homo sapiens* VH (IGHV5-51*01 (94.90%) -(IGHD)-IGHJ3*02) [8.8.12] (1-119) -IGHG1*03 (120-449)], (222-215')-disulfuro con la cadena ligera kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (100.00%) -IGKJ1*01) [7.3.9] (1'-108') -IGKC*01 (109'-215')]; dímero (228-228":231-231")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

EVQLVQSGAE	VKKSAGESLKI	SCKGSQSYST	SYWIGWVRQM	PGKGLEWMGI	50
FYPGDSSTRY	SPSFQGGVTI	SADKSVNTAY	LQWSSSLKASD	TAMYCCARRR	100
NWGNADFIDW	QGTMTVTSSA	STKGPSVFPL	APSSKSTSGG	TAALGCLVKD	150
YFPEPVTWSW	NSGALTSGVH	TFPAVLQSSG	LYSLSSVVTV	PSSSLGTQTY	200
ICNVNHKPSN	TKVDKRVPEK	SCDKTHTCPP	CPAPELLGGF	SVFLFPPKPK	250
DTLMISRTP	VTCVVVDVSH	EDPEVKFNWY	VDGVEVHNAK	TKPREEQYNS	300
TYRVVSVLT	VHQLDNLNKE	YKCKVSNKAL	PAPIEKTISK	AKGQPREPQV	350
YTLPPSRREEM	TKNQVSLTCL	VKGFPYSDIA	VEWESNGQPE	NNYKTTPPV	400
DSDGSFFFLYS	KLTVDKSRWQ	QGNVFSCSVM	HEALHNHYTQ	KSLSLSPGK	449

Light chain / Chaîne légère / Cadena ligera

EIVLTQSPGT	LSLSPGERAT	LSCRASQSVS	SSYLAWYQQK	PGQAPRLLIY	50
GASSRATGIP	DRFSGSGSGT	DFTLTISRLE	PEDFAVYYCQ	QYGSSTWTFG	100
QGTKVEIKRT	VAAPSVFIFP	PSDEQLKSGT	ASVVCCLNNF	YPREAKVQWK	150
VDNALQSGNS	QESVTEQDSK	DSTYSLSTSL	TLSKADYEKH	KVYACEVTHQ	200
GLSSPVTKSF	NRGEC				215

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H	22-96	146-202	263-323	369-427
	22"-96"	146"-202"	263"-323"	369"-427"
Intra-L	23'-89'	135'-195'		
	23'''-89'''	135'''-195'''		
Inter-H-L	222-215'	222"-215'"		
Inter-H-H	228-228"	231-231"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
299, 299"

aladorianum


aladorian

(7-methoxy-2,3-dihydro-1,4-benzothiazepin-4(5*H*)-yl)oxoacetic acid

aladorian

acide (7-méthoxy-2,3-dihydro-1,4-benzothiazépin-4(5*H*)-yl)oxoacétique

aladorián

ácido (7- metoxi-2,3-dihidro-1,4-benzotiazepin-4(5*H*)-il)oxoacéticoC₁₂H₁₃NO₄S**alirocumabum #**

alirocumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* PCSK9 (proprotein convertase subtilisin/kexin type 9)], *Homo sapiens* monoclonal antibody;gamma1 heavy chain (1-447) [*Homo sapiens* VH (IGHV3-23*04 (89.80%) -(IGHD)-IGHJ2*01 [8.8.11] (1-118) -IGHG1*01 CHS K2>del (119-447)], (221-220')-disulfide with kappa light chain (1'-220') [*Homo sapiens* V-KAPPA (IGKV4-1*01 (94.10%) -IGKJ2*01 [12.3.9] (1'-113') -IGKC*01 (114'-220'))]; (227-227'':230-230'')-bisdisulfide dimer

alirocumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* PCSK9 (proprotéine convertase subtilisine/kexine type 9)], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma1 (1-447) [*Homo sapiens* VH (IGHV3-23*04 (89.80%) -(IGHD)-IGHJ2*01 [8.8.11] (1-118) -IGHG1*01 CHS K2>del (119-447)], (221-220')-disulfure avec la chaîne légère kappa (1'-220') [*Homo sapiens* V-KAPPA (IGKV4-1*01 (94.10%) -IGKJ2*01 [12.3.9] (1'-113') -IGKC*01 (114'-220'))]; dimère (227-227'':230-230'')-bisdisulfure

alirocumab

immunoglobulina G1-kappa, anti-[PCSK9 de *Homo sapiens* (proteína convertasa subtilisina/kexina tipo 9)], anticuerpo monoclonal de *Homo sapiens*;
cadena pesada gamma1 (1-447) [*Homo sapiens* VH (IGHV3-23*04 (89.80%) -(IGHD)-IGHJ2*01 [8.8.11] (1-118) -IGHG1*01 CHS K2>del (119-447)], (221-220')-disulfuro con la cadena ligera kappa (1'-220') [*Homo sapiens* V-KAPPA (IGKV4-1*01 (94.10%) -IGKJ2*01 [12.3.9] (1'-113') -IGKC*01 (114'-220'))]; dímero (227-227'':230-230'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

EVQLVESGGG LVQPGGSLRL SCAASSGFTFN NYAMNWRQA PGKGLDWVST 50
 ISGSGGTTNY ADSVKGRFII SRDSSKHTLY LQMNSLRAED TAVYYCAKDS 100
 NWGNFDLWGR GTLVTSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
 FPEFVTSWN SGALTSVHT FPAVLQSSGL YSLSSVTVFP SSSSLGTQTYI 200
 CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD 250
 TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300
 YRVVSVLTIVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350
 TLPFSRDELK KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400
 SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPG 447

Light chain / Chaîne légère / Cadena ligera

DIVMTQSPDS LAVSLGERAT INCKSSQSVL YRSNNRNLFLG WYQQKPGQPP 50
 NLLIYWASTR ESGVPDRFSG SGSGTDFTLT ISSLAEDVA VYYCQYYTT 100
 PYTFGQGTKL EIKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNNFYPREA 150
 KVQWKVDNAL QSGNSQESVT EQDSKDSYLS LSSTLTLSKA DYEKHKVYAC 200
 EVTHQGLSPS VTKSFNRGEC 220

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 145-201 262-322 368-426
 22"-96" 145"-201" 262"-322" 368"-426"
 Intra-L 23'-94' 140'-200'
 23"-94" 140"-200"
 Inter-H-L 221-220' 221"-220"
 Inter-H-H 227-227" 230-230"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
 298, 298"

antithrombin gamma #
 antithrombin gamma

afucosylated antithrombin; human antithrombin-III (ATIII, serpin C1)
 expressed in fucosyl transferase-negative Chinese Hamster Ovary
 (CHO) cells (glycoform gamma)

antithrombine gamma

antithrombine afucosylée; antithrombine-III humaine (ATIII, serpine
 C1) obtenue à partir de culture de cellules ovariennes d'hamster
 chinois (CHO) n'exprimant pas la fucosyl transférase (glycoforme
 gamma)

antitrombina gamma


antitrombina afucosilada; antitrombina-III humana (ATIII, serpina C1)
 obtenida a partir de cultivo de células ováricas de hamster chino
 (CHO) que no expresan la fucosil transferasa (glicoforma gamma)

HGSPVDICTA KPRDIPMNPM CIYRSPEKKA TEDEGSEQKI PEATNRRVWE 50
 LSKANSRFAT TFYQHLADSK NDNDNIFLSP LSISTAFAMT KLGACNDTLQ 100
 QLMEVFKFDT ISEKTSQDIH FFFAKLNCRL YRKANKSSKL VSANRLFGDK 150
 SLTFNETYQD ISELVYGAKL QPLDFKENAE QSRAAINKWV SNKTEGRITD 200
 VIPSEAINEL TVLVLVNTIY FKGLWKSFKS PENTRKELFY KADGESCSAS 250
 MMYQEGKFRY RRVAEGTQVL ELFPKGDDIT MVLILPKPEK SLAKVEKELT 300
 PEVLQEWLDE LEEMMLVHM PRFRIEDGFS LKEQLQDMGL VDLFSPEKSK 350
 LFGIVAEGRD DLYVSDAFHK AFLEVNEEGS EAAASTAVVI AGRSLNPNRV 400
 TFKANRPFLV FIREVPLNTI IFMGRVANPC VK 432

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

8-128 21-95 247-430

Modified residue / Résidu modifié / Residuo modificado



Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)

Asn-96 Asn-135 Asn-155 Asn-192

$\alpha\text{-Sia} \rightarrow 3\text{-}\beta\text{-Gal} \rightarrow 3\text{-}\beta\text{-Gl-N} \rightarrow 2\text{-}\alpha\text{-Man} \rightarrow 6\text{-}\beta\text{-Man} \rightarrow 4\text{-}\beta\text{-Gl-N} \rightarrow 4\text{-}\beta\text{-Gl-N} \rightarrow \underline{\text{N}}$
 $\alpha\text{-Sia} \rightarrow 3\text{-}\beta\text{-Gal} \rightarrow 3\text{-}\beta\text{-Gl-N} \rightarrow 2\text{-}\alpha\text{-Man} \rightarrow 3\text{-}\beta\text{-Man} \rightarrow 4\text{-}\beta\text{-Gl-N} \rightarrow 4\text{-}\beta\text{-Gl-N} \rightarrow \underline{\text{N}}$

asudemotidum

asudemotide

human DEP domain-containing protein 1A-(294-302)-peptide

asudémotide

protéine 1A humaine contenant le domaine DEP-(294-302)-peptide

asudemotida

proteína 1A humana que contiene el dominio DEP-(294-302)-péptido

 $C_{58}H_{80}N_{10}O_{17}$

H—Glu—Tyr—Tyr—Glu—Leu—Phe—Val—Asn—Ile—OH

auriclosenum

auriclosene


2-(dichloroamino)-2-methylpropane-1-sulfonic acid

auriclosène

acide 2-(dichloroamino)-2-méthylpropane-1-sulfonique

auricloseno

ácido 2-(dicloroamino)-2-metilpropano-1-sulfónico

 $C_4H_9Cl_2NO_3S$ **avatrombopagum**

avatrombopag


1-(3-chloro-5-[[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)-1,3-thiazol-2-yl]carbamoyl]pyridin-2-yl)piperidine-4-carboxylic acid

avatrombopag

acide 1-(3-chloro-5-[[4-(4-chlorothiophén-2-yl)-5-(4-cyclohexylpipérazin-1-yl)-1,3-thiazol-2-yl]carbamoyl]pyridin-2-yl)pipéridine-4-carboxylique

avatrombopag

ácido 1-(3-cloro-5-[[5-(4-ciclohexilpiperazin-1-il)-4-(4-clorotiofen-2-il)-1,3-tiazol-2-il]carbamoi]piridin-2-il)piperidina-4-carboxílico

 $C_{29}H_{34}Cl_2N_6O_3S_2$ **balugrastimum #**

balugrastim

human serum albumin (585 residues) fusion protein with des-(1-alanine,37-valine,38-serine,39-glutamic acid)-human granulocyte colony-stimulating factor (pluripoietin)

balugrastim

albumine sérique humaine (585 résidus) protéine de fusion avec le dés-(1-alanine,37-valine,38-sérine,39-acide glutamique)-facteur de stimulation des colonies de granulocytes humain (pluripoétine)

balugrastim

albumina sérica humana (585 residuos) proteína de fusión con el des-(1-alanina,37-valina,38-serina,39-ácido glutámico)-factor humano estimulante de las colonias de granulocitos (pluripoyetina)

DAHKSEVAHR FDKLGEENFK ALVLIAPAY LQQCPFEDHV KLVNEVTEFA 50
 KTCVADESAE NCDKSLHTLF GDKLCTVATL RETYGMADAC CAKQEPERNE 100
 CFLQHKDDNP NLPRLVRPEV DVMCTAFHDN EETFLKKYLY EIARRHPYFY 150
 APELLFFAKR YKAAFECCQ AADKAACLLP KLDELKDEGK ASSAKQRLKC 200
 ASLQKFGERA FKAAVARLS QRFPAEFAE VSKLVTDLTK VHTECCGDL 250
 LECADDRADL AKYICENQDS ISSKLKECCE KPLLEKSHCI AEVENDEMPA 300
 DLPSLAADFV ESKDVCKNYA EAKDVFLGMF LYEYARRHFD YSVVLLRLA 350
 KTYETTLEKC CAAADPHECY AKVFDEFKPL VEEFQNLIKQ NCELFEQIGE 400
 YKFQNALLRV YTKKVPQVST PTLVEVSRNL GKVGSKCKKH PEAKRMPAE 450
 DYLSVVNLQL CVLHEKTPVS DRVTCKCTES LVNRRPCFSA LEVDETYVPK 500
 EFNAETFTFH ADICTLSEKE RQIKKQTALV ELVKHKPKAT KEQLKAVMDD 550
 FAAFVEKCKC ADDKETCFAE EGKKLVAAASQ AALGLTPLGP ASSLPQSFL 600
 KCLEQVRKIQ GDGAALQEKL CATYKLCHPE ELVLLGHSLG IPWAPLSSCP 650
 SQALQLAGCL SQLHSGFLY QGLLQALEGI SPELGPTLDT LQLDVADFAT 700
 TIWQMEELG MAPALQPTQG AMPAFASAFQ RRAGGVLVAS HLQSFLEVS 750
 RVLRLHAQP 759

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 53-62 75-91 90-101 124-169 168-177 200-246 245-253
 265-279 278-289 316-361 360-369 392-438 437-448 461-477
 476-487 514-559 558-567 621-627 649-659

baricitinibum

baricitinib


{1-(ethanesulfonyl)-3-[4-(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)-1*H*-pyrazol-1-yl]azetidin-3-yl}ethanenitrile

baricitinib

{1-(éthanesulfonyl)-3-[4-(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)-1*H*-pyrazol-1-yl]azétidin-3-yl}éthanenitrile

baricitinib

{1-(etanosulfonil)-3-[4-(7*H*-pirrolo[2,3-*d*]pirimidin-4-il)-1*H*-pirazol-1-il]azetidin-3-il}etanonitrilo

C₁₆H₁₇N₇O₂S**bevenopranum**

bevenopran


5-[2-methoxy-4-({[2-(oxan-4-yl)ethyl]amino}methyl)phenoxy]pyrazine-2-carboxamide

bévéno pran

5-[2-méthoxy-4-({[2-(oxan-4-yl)éthyl]amino}méthyl)phénoxy]pyrazine-2-carboxamide

bevenopran

5-[2-metoxi-4-({[2-(oxan-4-il)etil]amino}metil)fenoxi]pirazina-2-carboxamida

C₂₀H₂₆N₄O₄

bezlotoxumabum #

bezlotoxumab

immunoglobulin G1-kappa, anti-[*Clostridium difficile* toxin B)], *Homo sapiens* monoclonal antibody;
gamma1 heavy chain (1-449) [*Homo sapiens* VH (IGHV5-51*01 (94.90%) -(IGHD)-IGHJ3*02 [8.8.12] (1-119) -IGHG1*03 (120-449)], (222-215')-disulfide with kappa light chain (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (100.00%) -IGKJ1*01 [7.3.9] (1'-108') -IGKC*01 (109'-215'))]; (228-228":231-231")-bisdisulfide dimer

bezlotoxumab

immunoglobuline G1-kappa, anti-[*Clostridium difficile* toxine B)], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma1 (1-449) [*Homo sapiens* VH (IGHV5-51*01 (94.90%) -(IGHD)-IGHJ3*02 [8.8.12] (1-119) -IGHG1*03 (120-449)], (222-215')-disulfure avec la chaîne légère kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (100.00%) -IGKJ1*01 [7.3.9] (1'-108') -IGKC*01 (109'-215'))]; dimère (228-228":231-231")-bisdisulfure

bezlotoxumab

immunoglobulina G1-kappa, anti-[toxina B de *Clostridium difficile*], anticuerpo monoclonal de *Homo sapiens*;
cadena pesada gamma1 (1-449) [*Homo sapiens* VH (IGHV5-51*01 (94.90%) -(IGHD)-IGHJ3*02 [8.8.12] (1-119) -IGHG1*03 (120-449)], (222-215')-disulfuro con la cadena ligera kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (100.00%) -IGKJ1*01 [7.3.9] (1'-108') -IGKC*01 (109'-215'))]; dímero (228-228":231-231")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVQSGAE VKKSGESLKI SCKGSGYSFT SYWIGWVRQM PGKGLEWMGI 50
FYPGDSSTRY SPSFQGQVTI SADKSVNTAY LQWSSLKASD TAMYYCARRR 100
NWGNAFDIWG QGTMVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFFAVLQSSG LYSLSSTVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKRVFEPK SCDKTHTCPP CPAPELLGSP SVFLFPPKPK 250
DTLMISRTPE VTCVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSREEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTPPVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK 449
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPGT LSLSPGERAT LSCRASQSVS SSYLAWYQQK PGQAPRLLIY 50
GASSRATGIP DRFSGSGSGT DFTLTISRLE PEDFAVYCCQ QYGSSTWTFG 100
QGTEKVEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPBREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYSLSTL TLISKADYEH KVIYACEVTHQ 200
GLSSPVTKSF NRGEK 215
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H 22-96 146-202 263-323 369-427
          22"-96" 146"-202" 263"-323" 369"-427"
Intra-L 23'-89' 135'-195'
          23'"-89'" 135'"-195'"
Inter-H-L 222-215' 222"-215'"
Inter-H-H 228-228" 231-231"
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
299, 299"

birinapantum

birinapant



N,N'-[(6,6'-difluoro[1*H*,1'*H*-2,2'-biindole]-3,3'-diyl)bis(methylene[(2*R*,4*S*)-4-hydroxypyrrolidine-2,1-diyl]](2*S*)-1-oxobutane-1,2-diyl] bis[(2*S*)-2-(methylamino)propanamide]

birinapant

N,N'-[(6,6'-difluoro[1*H*,1'*H*-2,2'-biindole]-3,3'-diyl)bis(méthylène[(2*R*,4*S*)-4-hydroxypyrrolidine-2,1-diyl]](2*S*)-1-oxobutane-1,2-diyl]]bis[(2*S*)-2-(méthylamino)propanamide]

birinapant

N,N'-[(6,6'-difluoro[1*H*,1'*H*-2,2'-biindol]-3,3'-diil)bis(metileno[(2*R*,4*S*)-4-hidroxiporrolidina-2,1-diil]](2*S*)-1-oxobutano-1,2-diilo]bis[(2*S*)-2-(metilamino)propanamida]





blisibimodum #
blisibimod

B-cell activating factor (BAFF)-binding peptide fragment/human IgG1 Fc fusion protein;
glycyl-L-cysteinyl-L-lysyl-L-tryptophyl-[[29-isoleucine(V>I),30-lysine(R>K),31-glutamine(H>Q)]human tumor necrosis factor receptor superfamily member 13C (BAFF receptor, CD268)-(26-31)-peptidyl]-L-tryptophyl-L-valyl-L-cysteinyl-L-aspartyl-L-prolyl-L-leucylglycyl-L-serylglycyl-L-seryl-L-alanyl-L-threonylglycylglycyl-L-serylglycyl-L-seryl-L-threonyl-L-alanyl-L-seryl-L-serylglycyl-L-serylglycyl-L-seryl-L-alanyl-L-threonyl-L-histidyl-L-methionyl-L-leucyl-L-prolylglycyl-L-cysteinyl-L-lysyl-L-tryptophyl-[[29-isoleucine(V>I),30-lysine(R>K),31-glutamine(H>Q)]human tumor necrosis factor receptor superfamily member 13C (BAFF receptor, CD268)-(26-31)-peptidyl]-L-tryptophyl-L-valyl-L-cysteinyl-L-aspartyl-L-prolyl-L-leucylpentaglycyl-L-valyl-(human immunoglobulin heavy constant gamma 1 Fc-(6-232)-peptide) dimer (69-69':72-72')-bisdisulfide

blisibimod

protéine de fusion entre le fragment Fc de l'immunoglobuline G1 humaine et un fragment du peptide se liant au facteur d'activation des cellules B (BAFF);
glycyl-L-cystéinyl-L-lysyl-L-tryptophyl-[[29-isoleucine(V>I),30-lysine(R>K),31-glutamine(H>Q)]membre 13C de la superfamille des récepteurs humains du facteur de nécrose tumorale (TNF) (récepteur du BAFF, CD268)-(26-31)-peptidyl]-L-tryptophyl-L-valyl-L-cystéinyl-L-aspartyl-L-prolyl-L-leucylglycyl-L-serylglycyl-L-séryl-L-alanyl-L-thréonylglycylglycyl-L-serylglycyl-L-séryl-L-thréonyl-L-alanyl-L-séryl-L-serylglycyl-L-serylglycyl-L-séryl-L-alanyl-L-thréonyl-L-histidyl-L-méthionyl-L-leucyl-L-prolylglycyl-L-cystéinyl-L-lysyl-L-tryptophyl-[[29-isoleucine(V>I),30-lysine(R>K),31-glutamine(H>Q)]membre 13C de la superfamille des récepteurs humains du TNF (récepteur du BAFF, CD268)-(26-31)-peptidyl]-L-tryptophyl-L-valyl-L-cystéinyl-L-aspartyl-L-prolyl-L-leucylpentaglycyl-L-valyl-(fragment Fc de la chaîne lourde gamma 1 de l'immunoglobuline humaine-(6-232)-peptide), (69-69':72-72')-bisdisulfure du dimère

blisibimod	<p>proteína de fusión entre el fragmento Fc de la inmunoglobulina G1 humana y un fragmento del péptido que se une al factor de activación de las células B (BAFF); glicil-L-cisteinil-L-lisil-L-triptofil-[[29-isoleucina(V>I),30-lisina(R>K),31-glutamina(H>Q)]miembro 13C de la superfamilia de receptores humanos del factor de necrosis tumoral (TNF) (receptor del BAFF, CD268)-(26-31)-peptidil]-L-triptofil-L-valil-L-cisteinil-L-aspartil-L-prolil-L-leucilglicil-L-serilglicil-L-seril-L-alanil-L-treonilglicilglicil-L-serilglicil-L-seril-L-treonil-L-alanil-L-seril-L-serilglicil-L-serilglicil-L-seril-L-alanil-L-treonil-L-histidil-L-metionil-L-leucil-L-proilglicil-L-cisteinil-L-lisil-L-triptofil-[[29-isoleucina(V>I),30-lisina(R>K),31-glutamina(H>Q)]miembro 13C de la superfamilia de receptores humanos del TNF (receptor del BAFF, CD268)-(26-31)-peptidil]-L-triptofil-L-valil-L-cisteinil-L-aspartil-L-prolil-L-leucilpentaglicil-L-valil-(fragmento Fc de la cadena pesada gamma 1 de la inmunoglobulina humana-(6-232)-péptido), (69-69':72-72')-bisdisulfuro del dímero</p> <p>Monomer / Monomère / Monómero GCKWDLLIKQ WVCDDLPGSGS ATGGSGSTAS SGSGSATHML PGCKWDLLIK 50 QWVCDDLPGG GGVDKTHTCP PCPAPELLGG PSVFLFPPKP KDTLMISRT 100 EVTCCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN STYRVVSVLT 150 VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSRDE 200 LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTFPV LDSDGFFLY 250 SKLTVDKSRW QQGNVFCSV MHEALHNHYT QKSLSLSPGK 290</p> <p>Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro 2-13 2'-13' 43-54 43'-54' 69-69' 72-72' 104-164 104'-164' 210-268 210'-268'</p>
burlulipasum # burlulipase	<p>lipase (triacylglycerol lipase, EC-3.1.1.3) which amino acids sequence is common to <i>Burkholderia plantarii</i> and <i>Burkholderia glumae</i></p>
burlulipase	<p>lipase (triacylglycérol lipase, EC-3.1.1.3) dont la séquence d'acides aminés est commune à <i>Burkholderia plantarii</i> et <i>Burkholderia glumae</i></p>
burlulipasa	<p>lipasa (triacilglicerol lipasa, EC-3.1.1.3) cuya secuencia de aminoácidos es comuna a <i>Burkholderia plantarii</i> y <i>Burkholderia glumae</i></p> <p>ADTYAATRYP VILVHGLAGT DKFANVVDYW YGIQSDLQSH GAKVYVANLS 50 GFQSDDDGPN RGEQLLAYVK QVLAATGATK VNLIGHSQGG LTRSYVAAVA 100 PQLVASVTTI GTPHRGSEFA DFVQDVLKTD PTGLSSSTVIA AFINVFGTLV 150 SSSHNTDQDA LAALRTLTTA QTATYNRNFP SAGLGAPGSC QTGAATETVG 200 GSQHLLYSWG GTAIQPTSTV LGVTGATDTS TGTLDVANVT DPSTLALLAT 250 GAVMINRASG QNDGLVSRCS SLFGQVISTS YHWNHLDEIN QLLGVRGANA 300 EDPVAVIRTH VNRLKLQGV 319</p> <p>Disulfide bridge location / Position du pont disulfure / Posición del puente disulfuro 190-269</p>
cebranopadolum cebranopadol	<p><i>trans</i>-6'-fluoro-<i>N,N</i>-dimethyl-4-phenyl-4',9'-dihydro-3'<i>H</i>-spiro[cyclohexane-1,1'-pyrano[3,4-<i>b</i>]indol]-4-amine</p>
cébranopadol	<p><i>trans</i>-6'-fluoro-<i>N,N</i>-diméthyl-4-phényl-4',9'-dihydro-3'<i>H</i>-spiro[cyclohexane-1,1'-pyrano[3,4-<i>b</i>]indol]-4-amine</p>
cebranopadol	<p><i>trans</i>-4-fenil-6'-fluoro-<i>N,N</i>-dimetil-4',9'-dihidro-3'<i>H</i>-espiro[ciclohexano-1,1'-pirano[3,4-<i>b</i>]indol]-4-amina</p>

**cindunistatum**

cindunistat



S-[2-(acetimidoylamino)ethyl]-2-methyl-L-cysteine

cindunistat

S-[2-(acétimidoylamino)éthyl]-2-méthyl-L-cystéine

cindunistat

S-[2-(acetimidoilamino)etil]-2-metil-L-cisteina

**clazakizumabum #**

clazakizumab


immunoglobulin G1-kappa, anti-[*Homo sapiens* IL6 (interleukin 6, IL-6)], humanized monoclonal antibody;
 gamma1 heavy chain (1-450) [humanized VH (*Homo sapiens*IGHV3-66*01 (83.50%) -(IGHD)-IGHJ3*02 M123>L (115)) [8.8.14] (1-120) -*Homo sapiens*IGHG1*03 CH2 N84.4>A (300) (121-450)], (223-217')-disulfide with kappa light chain (1'-217') [humanized V-KAPPA (*Homo sapiens*IGKV1-39*01 (89.10%) -IGKJ4*01) [6.3.12] (1'-110') -*Homo sapiens*IGKC*01 (111'-217')]; (229-229":232-232")-bisdisulfide dimer

clazakizumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* IL6 (interleukine 6, IL-6)], anticorps monoclonal humanisé;
 chaîne lourde gamma1 (1-450) [VH humanisé (*Homo sapiens*IGHV3-66*01 (83.50%) -(IGHD)-IGHJ3*02 M123>L (115)) [8.8.14] (1-120) -*Homo sapiens*IGHG1*03 CH2 N84.4>A (300) (121-450)], (223-217')-disulfure avec la chaîne légère kappa (1'-217') [V-KAPPA humanisé (*Homo sapiens*IGKV1-39*01 (89.10%) -IGKJ4*01) [6.3.12] (1'-110') -*Homo sapiens*IGKC*01 (111'-217')]; dimère (229-229":232-232")-bisdisulfure

clazakizumab

immunoglobulina G1-kappa, anti-[IL6 de *Homo sapiens* (interleukina 6, IL-6)], anticuerpo monoclonal humanizado;
 cadena pesada gamma1 (1-450) [VH humanizado (*Homo sapiens*IGHV3-66*01 (83.50%) -(IGHD)-IGHJ3*02 M123>L (115)) [8.8.14] (1-120) -*Homo sapiens*IGHG1*03 CH2 N84.4>A (300) (121-450)], (223-217')-disulfuro con la cadena ligera kappa (1'-217') [V-KAPPA humanizado (*Homo sapiens*IGKV1-39*01 (89.10%) -IGKJ4*01) [6.3.12] (1'-110') -*Homo sapiens*IGKC*01 (111'-217')]; dímero (229-229":232-232")-bisdisulfuro

	<div>Heavy chain / Chaîne lourde / Cadena pesada</div> <div>EVQLVESGGG LVQPGGSLRL SCAASGFSLS NYYVTWVRQA PGKGLEWVGI 50</div> <div>IYGSDETAYA TSAIGRFTIS RDNSKNTLYL QMNSLRAEDT AVYYCARDDS 100</div> <div>SDWDAKFNWL GQGTLTVTSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150</div> <div>DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTTQT 200</div> <div>YICNVNHKFS NTKVDKRVEP KSCDKHTTCP PCPAPELLGG PSVFLFPPKP 250</div> <div>KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYA 300</div> <div>STYRVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350</div> <div>VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTTPV 400</div> <div>LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK 450</div> <div>Light chain / Chaîne légère / Cadena ligera</div> <div>AIQMTQSPSS LSASVGRDVT ITCQASQSN NELSWMYQKP GKAPKLLIYR 50</div> <div>ASTLASGVPS RFGSGSGSTD FTLTISLQP DDFATYYCQ GYSLRNIDNA 100</div> <div>FGGGTKVEIK RTVAAPSVFI FPFSDEQLKS GTASVVCCLN NFYPREAKVQ 150</div> <div>WKVDNALQSG NSQESVTEQD SKDSTYSLSS TLTLSKADYE KHKVYACEVT 200</div> <div>HQGLSSPVTK SFNRGEC 217</div> <div>Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro</div> <div>Intra-H 22-95 147-203 264-324 370-428</div> <div>22"-95" 147"-203" 264"-324" 370"-428"</div> <div>Intra-L 23'-88" 137'-197"</div> <div>23'''-88''' 137'''-197'''</div> <div>Inter-H-L 223-217" 223"-217"</div> <div>Inter-H-H 229-229" 232-232"</div> <div>N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación</div> <div>None : H CH2 N84.4>A</div>
cobimetinib	[3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]{3-hydroxy-3-[(2S)-piperidin-2-yl]azetidin-1-yl}methanone
cobimétinib	[3,4-difluoro-2-(2-fluoro-4-iodoanilino)phényl]{3-hydroxy-3-[(2S)-pipéridin-2-yl]azétidin-1-yl}méthanone
cobimetinib	[3,4-difluoro-2-(2-fluoro-4-iodoanilino)fenil]{3-hidroxi-3-[(2S)-piperidin-2-il]azetidin-1-il}metanona
	<div>C₂₁H₂₁F₃IN₃O₂</div> <div></div>
crisantaspasum #	
crisantaspase	L-asparaginase (EC 3.5.1.1, L-asparagine amidohydrolase) <i>Erwinia chrysanthemi</i> tetramer α ₄
crisantaspase	L-asparaginase (EC 3.5.1.1, L-asparagine amidohydrolase) <i>Erwinia chrysanthemi</i> , tétramère α ₄
crisantaspasa	L-asparaginasa (EC 3.5.1.1, L-asparagina amidohidrolasa) de <i>Erwinia chrysanthemi</i> , tetrámero α ₄
	<div>C₁₅₄₆H₂₅₁₀N₄₃₂O₄₇₆S₉ (monomer)</div> <div>Monomer / Monomère / Monómero</div> <div>ADKLPNIVIL ATGGTIAGSA ATGTQTTGYK AGALGVDTLI AVPEVKKLA 50</div> <div>NVKGEQFSNM ASENMTGDIV LKLSQVRNEL LARDDVDGVV ITHGTDIVEE 100</div> <div>SAYFLHLTVK SDKPVVFVAA MRPATAISAD GPMNLLAVR VAGBKQSRGR 150</div> <div>GVMVVLNDRI GSARYITKTN ASTLDTFFKAN EGYLGVIIQ NRIYYQNRID 200</div> <div>KLHTRTSVFD VRGLTSLPKV DILYGYQDDP EYLYDAAIQH GVKGIYVYAGM 250</div> <div>GAGSVSVRGI AGMRKAMEKG VVIVIRSTRG NGIVPPDEEL PGLVSDSLNP 300</div> <div>AHARILLMLA LTRTSDPKVI QEYFHTY 327</div>

dactolisibum

dactolisib


2-methyl-2-(4-{3-methyl-2-oxo-8-(quinolin-3-yl)-
2,3-dihydroimidazo[4,5-c]quinolin-1-yl}phenyl)propanenitrile

dactolisib

2-méthyl-2-[4-[3-méthyl-2-oxo-8-(quinoléin-3-yl)-
2,3-dihydroimidazo[4,5-c]quinoléin-1-yl]phényl]propanenitrile

dactolisib

2-metil-2-(4-{3-metil-2-oxo-8-(quinolin-3-il)-2,3-dihidroimidazo[4,5-
c]quinolin-1-il}fenil)propanonitrilo

C₃₀H₂₃N₅O**danirixinum**

danirixin


1-(4-chloro-2-hydroxy-3-[[[(3S)-piperidine-3-sulfonyl]phenyl]-
3-(3-fluoro-2-methylphenyl)urea

danirixine

1-(4-chloro-2-hydroxy-3-[[[(3S)-pipéridine-3-sulfonyl]phényl]-
3-(3-fluoro-2-méthylphényl)urée


danirixina

1-(4-cloro-2-hidroxi-3-[[[(3S)-piperidina-3-sulfonil]fenil]-3-(3-fluoro-
2-metilfenil)urea

C₁₉H₂₁ClFN₃O₄S**demcizumabum #**

demcizumab

immunoglobulin G2-kappa, anti-[*Homo sapiens* DLL4 (delta-like 4)],
humanized monoclonal antibody;
gamma2 heavy chain (1-444) [humanized VH (*Homo sapiens*
IGHV1-18*01 (85.70%) -(IGHD)-IGHJ6*01 T123>L (114) [8.8.12] (1-
119) -*Homo sapiens* IGHG2*01 CHS K2>del (120-444)], (133-218')-
disulfide with kappa light chain (1'-218') [humanized V-KAPPA
(*Homo sapiens* IGKV4-1*01 (76.20%) -IGKJ1*01 Q120>G (104))
[10.3.9] (1'-111') -*Homo sapiens* IGKC*01 (112'-218')]; (221-
221":222-222":225-225":228-228")-tetrakisdisulfide dimer

demcizumab	immunoglobuline G2-kappa, anti-[<i>Homo sapiens</i> DLL4 (delta-like 4)], anticorps monoclonal humanisé; chaîne lourde gamma2 (1-444) [VH humanisé (<i>Homo sapiens</i> IGHV1-18*01 (85.70%) -(IGHD)-IGHJ6*01 T123>L (114) [8.8.12] (1-119) - <i>Homo sapiens</i> IGHG2*01 CHS K2>del (120-444)], (133-218)-disulfure avec la chaîne légère kappa (1'-218') [V-KAPPA humanisé (<i>Homo sapiens</i> IGKV4-1*01 (76.20%) -IGKJ1*01 Q120>G (104)) [10.3.9] (1'-111') - <i>Homo sapiens</i> IGKC*01 (112'-218')]]; dimère (221-221":222-222":225-225":228-228")-tétrakisdisulfure
demcizumab	immunoglobulina G2-kappa, anti-[DLL4 (delta-like 4) de <i>Homo sapiens</i>], anticuerpo monoclonal humanizado; cadena pesada gamma2 (1-444) [VH humanizado (<i>Homo sapiens</i> IGHV1-18*01 (85.70%) -(IGHD)-IGHJ6*01 T123>L (114) [8.8.12] (1-119) - <i>Homo sapiens</i> IGHG2*01 CHS K2>del (120-444)], (133-218)-disulfuro con la cadena ligera kappa (1'-218') [V-KAPPA humanizado (<i>Homo sapiens</i> IGKV4-1*01 (76.20%) -IGKJ1*01 Q120>G (104)) [10.3.9] (1'-111') - <i>Homo sapiens</i> IGKC*01 (112'-218')]]; dímero (221-221":222-222":225-225":228-228")-tetraakisdisulfuro Heavy chain / Chaîne lourde / Cadena pesada QVQLVQSGAE VKKPGASVKI SCKASGYSFT AYYIHWWKQA PGQGLEWIGY 50 ISSYNGATNY NQKFKGRVTF TTDSTSTAY MELRSLRSDD TAVYVCARDY 100 DYDVGMDYWG QGTLVTVSSA STKGPSVFPL APCSRSTSES TAALGCLVKD 150 YFPEPVTVSW NSGALTSGVH TFFAVLQSSG LYSLSVVTV PSSNFGTQTY 200 TCNVDHKPSN TKVDKTVVERK CCVECPPCPA PPVAGPSVFL FPPKPKDTLM 250 ISRTPEVTCV VVDVSHEDPE VQFNWYVDGV EVHNAKTKPR EEQFNSTFRV 300 VSVLTVVHQD WLNKKEYKCK VSNKGLPAPI EKTISKTKGQ PREPQVYTLF 350 PSREEMTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPMLDSDG 400 SFFLYSKLTV DKSRRWQGNV FSCSVMEAL HNHYTQKSLS LSPG 444 Light chain / Chaîne légère / Cadena ligera DIVMTQSPDS LAVSLGERAT ISCRASESVD NYGISFMKWF QQKPGQPPKL 50 LIYAASNQGS GVPDRFSGSG SGTDFTLTIS SLQAEDVAVY YCQQSKEVPW 100 TFGGGTKVEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV 150 QWKVDNALQS GNSQESVTEQ DSKDSTYSLT STLTLSKADY EKHKVYACEV 200 THQGLSSPVT KSFNRGEC 218 Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H 22-96 146-202 259-319 365-423 22"-96" 146"-202" 259"-319" 365"-423" Intra-L 23'-92' 138'-198' 23"'-92'" 138"'-198'" Inter-H-L 133-218' 133"-218" Inter-H-H 221-221" 222-222" 225-225" 228-228" N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación H CH2 N84.4: 295, 295"
elbimilastum	
elbimilast	N-(3,5-dichloropyridin-4-yl)-2-{1-[(4-fluorophenyl)methyl]-1 <i>H</i> -pyrrolo[2,3- <i>b</i>]pyridin-3-yl}-2-oxoacetamide
elbimilast	N-(3,5-dichloropyridin-4-yl)-2-{1-[(4-fluorophényl)méthyl]-1 <i>H</i> -pyrrolo[2,3- <i>b</i>]pyridin-3-yl}-2-oxoacétamide
elbimilast	N-(3,5-dicloropiridin-4-il)-2-{1-[(4-fluorofenil)metil]-1 <i>H</i> -pirrolo[2,3- <i>b</i>]piridin-3-il}-2-oxoacetamida C ₂₁ H ₁₃ Cl ₂ FN ₄ O ₂ 

elubrixinum

elubrixin


1-(2-chloro-3-fluorophenyl)-3-[4-chloro-2-hydroxy-3-(piperazine-1-sulfonyl)phenyl]urea

élubrixine

1-(2-chloro-3-fluorophényl)-3-[4-chloro-2-hydroxy-3-(pipérazine-1-sulfonyl)phényl]urée

elubrixina

1-(2-cloro-3-fluorofenil)-3-[4-cloro-2-hidroxi-3-(piperazina-1-sulfonyl)fenil]urea

C₁₇H₁₇Cl₂FN₄O₄S**empegfilgrastimum #**

empegfilgrastim

[1-(*N*-{4-[ω-methoxypoly(oxyethylene)]butyl}-L-methionine)]human granulocyte colony-stimulating factor (pluripoietin)

empegfilgrastim

[1-(*N*-{4-[ω-méthoxypoly(oxyéthylène)]butyl}-L-méthionine)]facteur de stimulation des colonies de granulocytes humain (pluripoïétine)

empegfilgrastim

[1-(*N*-{4-[ω-metoxipoli(oxietileno)]butil}-L-metionina)]factor humano de estimulación de las colonias de granulocitos (pluripoyetina)

MTPLGPASSL PQSFLKCLE QVRKIQGDGA ALQEKLCATY KLCHPEELVL 50
 LGHSLGIPWA PLSSCPSQAL QLAGCLSQLH SGLFLYQGLL QALEGISPEL 100
 GPTLDTLQLD VADFATTIWQ QMEELGMAPA LQPTQGAMPA FASAFQRRAG 150
 GVLVASHLQS FLEVSRYVLR HLAQPF 175


Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 37-43 65-75

Modified residue / Résidu modifié / Resto modificado

M

I

PEG-Met

**enobosarmum**


enobosarm

(2*S*)-3-(4-cyanophenoxy)-*N*-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide

énobosarm

(2*S*)-3-(4-cyanophénoxy)-*N*-[4-cyano-3-(trifluorométhyl)phényl]-2-hydroxy-2-méthylpropanamide

enobosarm


(2*S*)-3-(4-cianofenoxi)-*N*-[4-ciano-3-(trifluorometil)fenil]-2-hidroxi-2-metilpropanamidaC₁₉H₁₄F₃N₃O₃

enoticumabum # enoticumab	immunoglobulin G1-kappa, anti- <i>[Homo sapiens</i> DLL4 (delta-like 4)], <i>Homo sapiens</i> monoclonal antibody; gamma1 heavy chain (1-452) [<i>Homo sapiens</i> VH (IGHV3-33*01 (90.80%) -(IGHD)-IGHJ5*02) [8.8.16] (1-123) -IGHG1*01 CHS K2>del (124-452)], (226-214')-disulfide with kappa light chain (1'-214') [<i>Homo sapiens</i> V-KAPPA (IGKV3-11*01 (98.90%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (232-232':235-235'')-bisdisulfide dimer
énoticumab	immunoglobuline G1-kappa, anti- <i>[Homo sapiens</i> DLL4 (delta-like 4)], <i>Homo sapiens</i> anticorps monoclonal; chaîne lourde gamma1 (1-452) [<i>Homo sapiens</i> VH (IGHV3-33*01 (90.80%) -(IGHD)-IGHJ5*02) [8.8.16] (1-123) -IGHG1*01 CHS K2>del (124-452)], (226-214')-disulfure avec la chaîne légère kappa (1'-214') [<i>Homo sapiens</i> V-KAPPA (IGKV3-11*01 (98.90%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (232-232':235-235'')-bisdisulfure
enoticumab	inmunoglobulina G1-kappa, anti- <i>[Homo sapiens</i> DLL4 (delta-like 4)], anticuerpo monoclonal de <i>Homo sapiens</i> ; cadena pesada gamma1 (1-452) [<i>Homo sapiens</i> VH (IGHV3-33*01 (90.80%) -(IGHD)-IGHJ5*02) [8.8.16] (1-123) -IGHG1*01 CHS K2>del (124-452)], (226-214')-disulfuro con la cadena ligera kappa (1'-214') [<i>Homo sapiens</i> V-KAPPA (IGKV3-11*01 (98.90%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (232-232':235-235'')-bisdisulfuro
	<p>Heavy chain / Chaîne lourde / Cadena pesada</p> <p>QVQLVESGGG VVQPGKSLRL SCAASGFTFS SYGMHWVRQA PGKGLEWVSF 50 LWYDGTNKNY VESVKGRTI SRDNSKNMLY LEMNSLRAD TAVVYCARDH 100 DFRSGYEGWF DPWGQGLTIV VSSASTKGPS VFPLAPSSKS TSGGTAALGC 150 LVKDYFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG 200 TQTYICNVNH KPSNTKVDKK VEPKSCDKTH TCPPCPAPEL LGGPSPVFLFP 250 PKPKDTLMIS RTPEVCTVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE 300 QYNSTYRVVS VLTVLHQDWL NGKEYCKKVS NKALPAPIEK TISKAKGQPR 350 EPQVYTLPPS RDELTKNQVS LTCLVKGFYP SDIAVEWESN GQPPENNYKTT 400 FPVLDSDGSF FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTQKSLSL 450 PG 452</p> <p>Light chain / Chaîne légère / Cadena ligera</p> <p>EIVLTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKQ GQAPRLLIYD 50 ASNRAIGIPA RFGSGSGSTD FTLTISSELP EDFAVYYCQH RSNWPPFTFGG 100 GTRKVEIKRTV AAPSVEIFPP SDEQLKSGTA SVVCLLNIFY PREAKVQWKV 150 DNALQSGNSQ ESVTEQDSKD STYSLSSLT LSKADYEKKH VYACEVTHQG 200 LSSPVTKSFN RGE 214</p> <p>Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro</p> <p>Intra-H 22-96 150-206 267-327 373-431 22"-96" 150"-206" 267"-327" 373"-431"</p> <p>Intra-L 23'-88" 134'-194" 23'''-88''' 134'''-194'''</p> <p>Inter-H-L 226-214' 226"-214" Inter-H-H 232-232" 235-235"</p> <p>N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación</p> <p>H CH2 N84.4: 303, 303"</p>
ensereptidum ensereptide	acetyl(human lactotransferrin-(15-39)-peptidamide)
enséreptide	acétyl(lactotransferrine humaine-(15-39)-peptidamide)
ensereptida	acetil(lactotransferrina humana-(15-39)-peptidamida)

EATKCFQWQR NMRKVRGPPV SCIKR 25

Disulfide bridge location / Position du pont disulfure / Posición del puente disulfuro
5 - 22


Modified residues / Résidus modifiés / Restos modificados

**enzalutamidum**
enzalutamide4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl}-2-fluoro-*N*-methylbenzamide

enzalutamide

4-{3-[4-cyano-3-(trifluorométhyl)phényl]-5,5-diméthyl-4-oxo-2-sulfanylidèneimidazolidin-1-yl}-2-fluoro-*N*-méthylbenzamide


enzalutamida

4-{3-[4-ciano-3-(trifluorometil)fenil]-5,5-dimetil-4-oxo-2-sulfanilidenoimidazolidin-1-il}-2-fluoro-*N*-metilbenzamidaC₂₁H₁₆F₄N₄O₂S**ertugliflozinum**
ertugliflozin(1*S*,2*S*,3*S*,4*R*,5*S*)-5-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol

ertugliflozine

(1*S*,2*S*,3*S*,4*R*,5*S*)-5-{4-chloro-3-[(4-éthoxyphényl)méthyl]phényl}-1-(hydroxyméthyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol

ertugliflozina

(1*S*,2*S*,3*S*,4*R*,5*S*)-5-{4-cloro-3-[(4-etoxifenil)metil]fenil}-1-(hidroximetil)-6,8-dioxabicio[3.2.1]octane-2,3,4-triolC₂₂H₂₅ClO₇

etirinotecanum pegolum

etirinotecan pegol


tetrakis{(4*S*)-9-([1,4'-bipiperidine]-1'-carbonyloxy)-4,11-diethyl-3,14-dioxo-3,4,12,14-tetrahydro-1*H*-pyrano[3',4':6,7]indolizino[1,2-*b*]quinolin-4-yl} *N,N',N'',N'''*-{methanetetrayltetrakis[methylenepoly(oxyethylene)oxy(1-oxoethylene)]}tetraglycinate

étirinotécan pégol

N,N',N'',N'''-{méthanetétrayltétrakis[méthylènepoly(oxyéthylène)oxy(1-oxoéthylène)]}tétraglycinate de tétrakis{(4*S*)-9-([1,4'-bipéridine]-1'-carbonyloxy)-4,11-diéthyl-3,14-dioxo-3,4,12,14-tétrahydro-1*H*-pyrano[3',4':6,7]indolizino[1,2-*b*]quinoléin-4-yle}

etirinotecán pegol

N,N',N'',N'''-{metanotetrailtetrakis[metilenepoli(oxietilene)oxi(1-oxoetileno)]}tetraglicinato de tetrakis{(4*S*)-9-([1,4'-bipiperidina]-1'-carboniloxi)-4,11-dietil-3,14-dioxo-3,4,12,14-tetrahydro-1*H*-pirano[3',4':6,7]indolizino[1,2-*b*]quinolin-4-ilo}

 $C_{153}H_{176}N_{20}O_{36} [C_8H_{16}O_4]_n$
**evogliptinum**

evogliptin


(3*R*)-4-[(3*R*)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(*tert*-butoxymethyl)piperazin-2-one

évogliptine

(3*R*)-4-[(3*R*)-3-amino-4-(2,4,5-trifluorophényl)butanoyl]-3-(*tert*-butoxyméthyl)pipérazin-2-one

evogliptina

(3*R*)-4-[(3*R*)-3-amino-4-(2,4,5-trifluorofenil)butanoil]-3-(*terc*-butoximetil)piperazin-2-ona

 $C_{19}H_{26}F_3N_3O_3$
**fasiglifamum**

fasiglifam


[(3*S*)-6-((2',6'-dimethyl-4'-[3-(methanesulfonyl)propoxy]-[1,1'-biphenyl]-3-yl))methoxy)-2,3-dihydro-1-benzofuran-3-yl]acetic acid

fasiglifam

acide [(3S)-6-((2',6'-diméthyl-4'-[3-(méthanesulfonyl)propoxy]-[1,1'-biphényl]-3-yl)méthoxy)-2,3-dihydro-1-benzofuran-3-yl]acétique

fasiglifam

ácido [(3S)-6-((2',6'-dimetil-4'-[3-(metanosulfonyl)propoxi]-[1,1'-bifenil]-3-il))metoxi)-2,3-dihidro-1-benzofuran-3-il]acético

C₂₉H₃₂O₇S

fasinumabum #

fasinumab

immunoglobulin G4-kappa, anti-[*Homo sapiens* NGF (nerve growth factor, nerve growth factor beta polypeptide, NGFB, beta-NGF)], *Homo sapiens* monoclonal antibody;
 gamma4 heavy chain (1-446) [*Homo sapiens* VH (IGHV1-24*01 (95.90%) -(IGHD)-IGHJ5*01 [8.8.12] (1-119) -IGHG4*01 hinge S10>P (227) (120-446)], (133-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-17*01 (90.50%) -IGKJ1*01 [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (225-225':228-228'')-bisdisulfide dimer

fasinumab

immunoglobuline G4-kappa, anti-[*Homo sapiens* NGF (facteur de croissance du nerf, facteur de croissance du nerf polypeptide bêta, NGFB, bêta-NGF)], *Homo sapiens* anticorps monoclonal;
 chaîne lourde gamma4 (1-446) [*Homo sapiens* VH (IGHV1-24*01 (95.90%) -(IGHD)-IGHJ5*01 [8.8.12] (1-119) -IGHG4*01 charnière S10>P (227) (120-446)], (133-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-17*01 (90.50%) -IGKJ1*01 [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (225-225':228-228'')-bisdisulfure

fasinumab

immunoglobulina G4-kappa, anti-[NGF de *Homo sapiens* (factor de crecimiento neuronal, factor de crecimiento neuronal polipéptido beta, NGFB, beta-NGF)], anticuerpo monoclonal de *Homo sapiens*;
 cadena pesada gamma4 (1-446) [*Homo sapiens* VH (IGHV1-24*01 (95.90%) -(IGHD)-IGHJ5*01 [8.8.12] (1-119) -IGHG4*01 bisagra S10>P (227) (120-446)], (133-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-17*01 (90.50%) -IGKJ1*01 [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (225-225':228-228'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

QVQLVQSGAE	VKKPGASVKV	SCKVSGLT	ELSIHWVRQA	PGKGLEWMGG	50
FDPEDGETIY	AQKFQGRVTM	TEDTSTDTAY	MELTSLRSED	TAVYYCSTIF	100
GVVTNFDNWG	QGTLTIVSSA	STKGPSVFPL	APCSRSTSES	TAALGCLVKD	150
YFPEPVTWSW	NSGALTSQSV	TTPAVLQSSG	LYSLSSVTV	PSSSLGKTGY	200
TCNVDHKPSN	TKVDKRVESK	YGPPCPPCPA	PEFLGGPSVF	LFPPKPKDTL	250
MISRTPEVTC	VVVDVSQEDP	EVQFNWYVDG	VEVHNAKTKP	REEQFNSTYR	300
VVSVLTVLHQ	DWLNKKEYKC	KVSNKGLPSS	IEKTISKAKG	QPREPQVYTL	350
PPSQEEMTKN	QVSLTCLVKG	FYPSTIAVEW	ESNGQPENNY	KTTTPPVLDSD	400
GSFFLYSRLT	VDKSRWQEGN	VFSCSVMEHA	LHNHYTQKSL	SLSLGK	446

Light chain / Chaîne légère / Cadena ligera

DIQMTQSPSS	LSASAGDRV	ITCRASQAIR	NDLGWYQQK	GKAPKRLIYA	50
AFNLQSGVPS	RFSGSGSGTE	FTLTISLQ	EDLASYYCQ	YNRYPWTFGQ	100
GTKVEIKRTV	AAPSVFIFPP	SDEQLKSGTA	SVVCLLNFF	PREAKVQWKV	150
DNALQSGNSQ	ESVTEQDSKD	STYSLSTLT	LSKADYEKHK	VYACEVTHQG	200
LSPSVTSKFN	RGEC				214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H	22-96	146-202	260-320	366-424
	22"-96"	146"-202"	260"-320"	366"-424"

Intra-L	23'-88'	134'-194'
	23'''-88'''	134'''-194'''

Inter-H-L 133-214' 133"-214"

Inter-H-H 225-225" 228-228"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
296, 296"

firtecanum pegolum

firtecan pegol


tetrakis[(4*S*)-4,11-diethyl-9-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1*H*-pyrano[3',4':6,7]indolizino[1,2-*b*]quinolin-4-yl] *N,N',N'',N'''*-(oxybis[(propane-3,1,2-triyl)bis[poly(oxyethylene)oxy(1-oxoethylene)]]))tetraglycinate

firtécan pégol

N,N',N'',N'''-(oxybis[(propane-3,1,2-triyl)bis[poly(oxyéthylène)oxy(1-oxoéthylène)]]))tétraglycinate de tétrakis[(4*S*)-4,11-diéthyl-9-hydroxy-3,14-dioxo-3,4,12,14-tétrahydro-1*H*-pyrano[3',4':6,7]indolizino[1,2-*b*]quinoléin-4-yle]

firtecán pegol

N,N',N'',N'''-(oxibis[(propano-3,1,2-triil)bis[poli(oxietileno)oxi(1-oxoetileno)]]))tetraglicinato de tetrakis[(4*S*)-4,11-dietil-9-hidroxi-3,14-dioxo-3,4,12,14-tetrahidro-1*H*-pirano[3',4':6,7]indolizino[1,2-*b*]quinolin-4-ilo]

 $C_{110}H_{106}N_{12}O_{33} (C_2H_4O)_{4n}$
**fluralanerum**

fluralaner


4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]-2-methyl-*N*-(2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl)benzamide

fluralaner

4-[(5*RS*)-5-(3,5-dichlorophényl)-5-(trifluorométhyl)-4,5-dihydro-1,2-isoxazol-3-yl]-2-méthyl-*N*-(2-oxo-2-[(2,2,2-trifluoroéthyl)amino]éthyl)benzamide

fluralaner

4-[5-(3,5-diclorofenil)-5-(trifluorometil)-4,5-dihidro-1,2-oxazol-3-il]-2-metil-*N*-(2-oxo-2-[(2,2,2-trifluoroetil)amino]etil)benzamida

 $C_{22}H_{17}Cl_2F_6N_3O_3$


futuximabum #

futuximab

immunoglobulin G1-kappa, anti-[*Homo sapiens* EGFR (epidermal growth factor receptor, ERBB1, HER1) domain III], chimeric monoclonal antibody;
gamma1 heavy chain (1-452) [*Mus musculus* VH (IGHV1S5*01 - (IGHD)-IGHJ4*01) [8.8.16] (1-123) -*Homo sapiens* IGHG1*03 CHS K2>del (124-452)], (226-214')-disulfide with kappa light chain (1'-214') [*Mus musculus* V-KAPPA (IGKV10-96*01 -IGKJ1*02) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; (232-232'':235-235'')-bisdisulfide dimer

futuximab

immunoglobuline G1-kappa, anti-[*Homo sapiens* EGFR (récepteur du facteur de croissance épidermique ERBB1, HER1) domaine III], anticorps monoclonal chimérique;
chaîne lourde gamma1 (1-452) [*Mus musculus* VH (IGHV1S5*01 - (IGHD)-IGHJ4*01) [8.8.16] (1-123) -*Homo sapiens* IGHG1*03 CHS K2>del (124-452)], (226-214')-disulfure avec la chaîne légère kappa (1'-214') [*Mus musculus* V-KAPPA (IGKV10-96*01 -IGKJ1*02) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dimère (232-232'':235-235'')-bisdisulfure

futuximab

immunoglobulina G1-kappa, anti-[EGFR de *Homo sapiens* (receptor del factor de crecimiento epidérmico ERBB1, HER1) dominio III], anticuerpo monoclonal quimérico;
cadena pesada gamma1 (1-452) [*Mus musculus* VH (IGHV1S5*01 - (IGHD)-IGHJ4*01) [8.8.16] (1-123) -*Homo sapiens* IGHG1*03 CHS K2>del (124-452)], (226-214')-disulfuro con la cadena ligera kappa (1'-214') [*Mus musculus* V-KAPPA (IGKV10-96*01 -IGKJ1*02) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dímero (232-232'':235-235'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLQQPGSE LVRPGASVKL SCKASGYTFT SYWMHWVKQR PGQGLEWIGN 50
IYPGSRSTNY DEKFKSKATL TVDTSSSTAY MQLSSLTSED SAVYYCTRNG 100
DYYVSSGDAM DYWGQGTSTV VSSASTKGPS VFPLAPSSKS TSGGTAALGC 150
LVKDYFPEPV TVSWNSGALT SGVHTFFPAVL QSSGLYSLSS VVTVPSSSLG 200
TQTYICNVNH KPSNTKVDKR VEPKSCDKTH TCPPCPAPEL LGGFSVFLFP 250
PKPKDTLMIS RTPEVTCVVV DVSHEDEPKV FNWYVDGVEV HNAKTKPREE 300
QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK TISKARGQPR 350
EPQVYTLPPS REEMTKNQVS LTCLVKGFPY SDIAVWESN GPENNYKTT 400
PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS CSMVHEALHN HYTKSKLSLS 450
PG 452
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQTTSS LSASLGDRVT ISCRTSQDIG NYLWYQKQP DGTVKLLIYY 50
TSRLHSGVPS RFGSGSGSTD FSLTINNVEQ EDVATYFCQH YNTVPPTFGG 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC 214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H 22-96 150-206 267-327 373-431
        22"-96" 150"-206" 267"-327" 373"-431"
Intra-L 23'-88" 134'-194'
        23'''-88''' 134'''-194'''
Inter-H-L 226-214' 226"-214'"
Inter-H-H 232-232" 235-235"
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación


H CH2 84.4:
303, 303"

giminabantum

giminabant

3-chloro-4-((2*R*)-2-(4-chlorophenyl)-
4-[(1*R*)-1-(4-cyanophenyl)ethyl]piperazin-1-yl)benzonitrile

giminabant	3-chloro-4-[(2 <i>R</i>)-2-(4-chlorophényl)-4-[(1 <i>R</i>)-1-(4-cyanophényl)éthyl]pipérazin-1-yl]benzonitrile
giminabant	3-cloro-4-[(2 <i>R</i>)-2-(4-clorofenil)-4-[(1 <i>R</i>)-1-(4-cianofenil)etil]pipérazin-1-il]benzonitrilo

C₂₆H₂₂Cl₂N₄

golvatinibum
golvatinib


N-[2-fluoro-4-({2-[4-(4-methylpiperazin-1-yl)piperidine-1-carboxamido]pyridin-4-yl}oxy)phényl]-*N'*-(4-fluorophényl)cyclopropane-1,1-dicarboxamide

golvatinib

N-[2-fluoro-4-({2-[4-(4-méthylpipérazin-1-yl)pipéridine-1-carboxamido]pyridin-4-yl}oxy)phényl]-*N'*-(4-fluorophényl)cyclopropane-1,1-dicarboxamide

golvatinib

N-[2-fluoro-4-({2-[4-(4-metilpipérazin-1-il)pipéridina-1-carboxamido]piridin-4-il}oxi)fenil]-*N'*-(4-fluorofenil)ciclopropano-1,1-dicarboxamida

C₃₃H₃₇F₂N₇O₄

ibrutinibum
ibrutinib


1-[(3*R*)-3-[4-amino-3-(4-phenoxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one

ibrutinib

1-[(3*R*)-3-[4-amino-3-(4-phénoxyphényl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl]pipéridin-1-yl]prop-2-én-1-one

ibrutinib

1-[(3*R*)-3-[4-amino-3-(4-fenoxifenil)-1*H*-pirazolo[3,4-*d*]pirimidin-1-il]pipéridin-1-il]prop-2-en-1-ona

C₂₅H₂₄N₆O₂

idelalisibum


idelalisib

5-fluoro-3-phenyl-2-[(1*S*)-1-[(7*H*-purin-6-yl)amino]propyl]quinazolin-4(3*H*)-one

idélalisib

5-fluoro-3-phényl-2-[(1*S*)-1-(7*H*-purin-6-ylamino)propyl]quinazolin-4(3*H*)-one

idelalisib

5-fluoro-3-fenil-2-[(1*S*)-1-(7*H*-purin-6-ilamino)propil]quinazolin-4(3*H*)-onaC₂₂H₁₈FN₇O**imgatuzumabum #**

imgatuzumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* EGFR (epidermal growth factor receptor, ERBB1, HER1)], humanized monoclonal antibody;
 gamma1 heavy chain (1-449) [humanized VH (*Homo sapiens*IGHV1-46*01 (83.70%) -(IGHD)-IGHJ6*01 [8.8.13] (1-120) -*Homo sapiens*IGHG1*01 CHS K2>del (121-449)], (223-213')-disulfide with kappa light chain (1'-213') [humanized V-KAPPA (*Homo sapiens*IGKV1-17*01 (90.50%) -IGKJ2*01 [6.3.8] (1'-106') -*Homo sapiens*IGKC*01 (107'-213''))]; (229-229'':232-232'')-bisdisulfide dimer

imgatuzumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* EGFR (récepteur du facteur de croissance épidermique ERBB1, HER1)], anticorps monoclonal humanisé;
 chaîne lourde gamma1 (1-449) [VH humanisé (*Homo sapiens*IGHV1-46*01 (83.70%) -(IGHD)-IGHJ6*01 [8.8.13] (1-120) -*Homo sapiens*IGHG1*01 CHS K2>del (121-449)], (223-213')-disulfure avec la chaîne légère kappa (1'-213') [V-KAPPA humanisé (*Homo sapiens*IGKV1-17*01 (90.50%) -IGKJ2*01 [6.3.8] (1'-106') -*Homo sapiens*IGKC*01 (107'-213''))]; dimère (229-229'':232-232'')-bisdisulfure

imgatuzumab

inmunoglobulina G1-kappa, anti-[EGFR de *Homo sapiens* (receptor del factor de crecimiento epidérmico ERBB1, HER1)], anticuerpo monoclonal humanizado;
 cadena pesada gamma1 (1-449) [VH humanizado (*Homo sapiens*IGHV1-46*01 (83.70%) -(IGHD)-IGHJ6*01 [8.8.13] (1-120) -*Homo sapiens*IGHG1*01 CHS K2>del (121-449)], (223-213')-disulfuro con la cadena ligera kappa (1'-213') [V-KAPPA humanizado (*Homo sapiens*IGKV1-17*01 (90.50%) -IGKJ2*01 [6.3.8] (1'-106') -*Homo sapiens*IGKC*01 (107'-213''))]; dímero (229-229'':232-232'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada				
QVQLVQSGAE	VKKPKGSSVK	TKADGTFST	DYKIHWRQRA	PQGQLEWMGY 50
FNPNSSGYST	AQKQFGQRVT	SCAKSTST	MELSSLRSED	TAVYVCAKs 100
PGGYVYMDAW	QGQTTTVTVSS	ATKSGPSVFP	PLAPSSKSTCS	GTAALGCLVK 150
DFYFPEFVTS	WNSGALTKSG	HTFPVLQSS	GLYSLSVSVT	VPFSSSLGTQT 200
YICNVNHNKPS	NTKVDKTKVEP	KSCDKHTHCP	CPGAPPELLGG	VPFVLPFPKP 250
KDTLMIKSRP	ETVCVVVDVS	HEDPEVKFNH	YVDGEVHNHA	KTKPREEQYN 300
STRYRVSVLT	VLHQDWLNGK	EYKGFYSNKA	LPAIEKTIKS	KAKGQPRPEQ 350
VYTLPRPSRDE	LTKNQSLSLC	LVKCFYPSDI	AVEWESNGSD	ENNYKTTTPV 400
LDSGSGFFLY	SKLTVDKSRW	QQGNVFSCSV	MHEALHNHYT	QKSLSLSPG 449
Light chain / Chaîne légère / Cadena ligera				
DIQMTPSPSS	LSASVGDVRV	ITCRASQGIN	NYLWNYYQKP	GKAPKRLIYN 50
TNNLTQTGPS	RFSGSGSGTE	FDTLTISSLQ	EDPATYCYCLQ	HNSPFTFGGQ 100
TKLEIKRTVA	APSFVIFPPS	FLTKSGGTAS	VCVLNLFNRP	REAKVQWKVD 150
NALQSGNSQE	SVTEQDSKDS	TYLSLSSTLT	SKADYEKKHV	YACEVTHQGL 200
SSPVTKSFNR	GEC			213
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro				
Intra-H	22-96	147-203	264-324	370-428
	22'-96"	147"-203"	264"-324"	370"-428"
Intra-L	23'-88"	133"-193"		
	23"-88"	133"-193"		
Inter-H-L	223-213'	223"-213"		
Inter-H-H	229-229"	232-232"		

insulinum peglisprum
insulin peglispro


macrogol 20000 pegylated insulin lispro:
[28^B-(-6-*N*-[[ω-methoxypoly(oxyethylene)]carbonyl]-L-lysine),
29^B-L-proline]human insulin

insuline péglispro

insuline lispro pégylée avec du macrogol 20000:
[28^B-(6-*N*-[[ω-méthoxypoly(oxyéthylène)]carbonyl]-L-lysine),
29^B-L-proline]insuline humaine

insulina peglispro

insulina lispro pegilada con macrogol 20000:
[28^B-(6-N-[[ω-metoxipoli(oxietileno)]carbonil]-L-lisina),
29^B-L-prolina]insulina humana



lampalizumabum #
lampalizumab

immunoglobulin Fab G1-kappa, anti-[*Homo sapiens* CFD (complement factor D)], humanized monoclonal antibody; VH -(CH1-hinge) gamma1 heavy chain (1-223) [humanized VH (*Homo sapiens* IGHV7-4*1*02 (88.80%) -(IGHD)-IGHJ5*01) [8.8.] (1-115) -*Homo sapiens* IGHG1*01 CH1 (116-213), hinge 1-10 (214-223)], (218-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-33*01 (77.90%) -(IGKJ2*01 L124>V (104) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214'))]

lampalizumab

immunoglobuline Fab G1-kappa, anti-[*Homo sapiens* CFD (facteur D du complément)], anticorps monoclonal humanisé;
chaîne lourde VH -(CH1-chaînière) gamma1 (1-223) [VH humanisé (*Homo sapiens* IGHV7-4-1*02 (88.80%) -IGHD-IGHJ5*01) [8.8] (1-115) -*Homo sapiens* IGHG1*01 CH1 (116-213), chaînière 1-10 (214-223)], (218-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-33*01 (77.90%) -IGKJ2*01 L124>V (104) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]

lampalizumab

inmunoglobulina Fab G1-kappa, anti-[CFD (factor D del complemento) de *Homo sapiens*], anticuerpo monoclonal humanizado;
cadena pesada VH -(CH1-bisagra) gamma1 (1-223) [VH humanizado (*Homo sapiens*IGHV7-4-1*02 (88.80%) -(IGHD)-IGHJ5*01) [8.8.8] (1-115) -*Homo sapiens*IGHG1*01 CH1 (116-213), bisagra 1-10 (214-223)], (218-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens*IGKV1-33*01 (77.90%) -IGKJ2*01 L124>V (104) [6.3.9] (1'-107') -*Homo sapiens*IGKC*01 (108'-214')]

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVQSGPE LKKPGASVKV SCKASGYTFT NYGMNWRQA PGQGLEWMGW 50
INTYTGGETY ADDFKGRFVF SLDTSVSTAY LQISSLKAED TAVYYCEREG 100
GVNNWGQGTI VTVSSASTKG PSVFPLAPSS KSTSGGTAAL GCLVKDYFPE 150
PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVTVTPSSS LGTQTYICNV 200
NHKPSNTKVD KKVEPKSCDK THT 223
```

Light chain / Chaîne légère / Cadena ligera

```
DIQVTSQSPSS LSASVGDRVT ITCITSTDID DDMNMYQQKP GKVPKLLISG 50
GNTLRPGVPS RFGSGSGSTD FTLTISSLQF EDVATYYCLQ SDSLPYTFGQ 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNEY FREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYLSSTLT LSKADYERHK VYACEVTHQG 200
LSSPVTKSFN RGECE 214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 142-198
Intra-L 23'-88' 134'-194'
Inter-H-L 218-214'

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

None

latanoprostenum bunodum

latanoprostene bunod


4-(nitrooxy)butyl (5Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl)hept-5-enoate

latanoprostène bunod

(5Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phénylpentyl]cyclopentyl)hept-5-énoate de 4-(nitrooxy)butyle

latanoprosteno bunod

(5Z)-7-((1R,2R,3R,5S)-3,5-dihidroxi-2-[(3R)-3-hidroxi-5-fenilpentil]ciclopentil)hept-5-enoato de 4-(nitrooxi)butilo

C₂₇H₄₁NO₈

latromotidum

latromotide



human kinesin-like protein KIF20A-(66-75)-peptide

latromotide

membre 20A des protéines de la famille des kinésines humaines-(66-75)-peptide

latromotida

miembro 20A de las proteínas de la familia de las kinesinas humanas-(66-75)-péptido



lifitegrastum
lifitegrast



(2S)-2-{2-[(1-benzofuran-6-yl)carbonyl]]-5,7-dichloro-1,2,3,4-tetrahydroisoquinolin-6-carboxamido}-3-[3-(methanesulfonyl)phenyl]propanoic acid

lifitégrast

acide (2S)-2-{2-[(1-benzofuran-6-yl)carbonyl]]-5,7-dichloro-1,2,3,4-tétrahydroisoquinoléin-6-carboxamido}-3-[3-(méthanesulfonyl)phényl]propanoïque

lifitegrast

ácido (2S)-2-{2-[(1-benzofuran-6-il)carbonil]]-5,7-dicloro-1,2,3,4-tetrahidroisoquinolin-6-carboxamido}-3-[3-(metanosulfonyl)fenil]propanoico



ligelizumabum #
ligelizumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* IGHE (immunoglobulin constant epsilon (IGHE) region of the heavy chain of IgE) CH3 1.3-9 (12 AA), 108-121 (12 AA) epitope], humanized monoclonal antibody;
gamma1 heavy chain (1-453) [humanized VH (*Homo sapiens* IGHV1-69*11 (80.60%) -(IGHD)-IGHJ4*01) [8.8.16] (1-123) -*Homo sapiens* IGHG1*01 (124-453)], (226-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV3-15*01 (86.30%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; (232-232":235-235")-bisdisulfide dimer

ligélizumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* IGHE (région constante epsilon (IGHE) de la chaîne lourde des immunoglobulines IgE) épitope CH3 1.3-9 (12 AA), 108-121 (12 AA)], anticorps monoclonal humanisé;
chaîne lourde gamma1 (1-453) [VH humanisé (*Homo sapiens* IGHV1-69*11 (80.60%) -(IGHD)-IGHJ4*01) [8.8.16] (1-123) - *Homo sapiens* IGHG1*01 (124-453)], (226-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV3-15*01 (86.30%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dimère (232-232":235-235")-bisdisulfure

ligelizumab

immunoglobulina G1-kappa, anti-[IGHE de *Homo sapiens* (región constante epsilon (IGHE) de la cadena pesada de las inmunoglobulinas IgE) epítipo CH3 1.3-9 (12 AA), 108-121 (12 AA)], anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-453) [VH humanizada (*Homo sapiens*IGHV1-69*11 (80.60%) -(IGHD)-IGHJ4*01) [8.8.16] (1-123) -*Homo sapiens*IGHG1*01 (124-453)], (226-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens*IGKV3-15*01 (86.30%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens*IGKC*01 (108'-214')]; dímero (232-232":235-235")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```

QVQLVQSGAE VMKPGSSVKV SCKASGYTFS WYWEWVRQA PGHGLEWMGE 50
IDPGTFTTNY NEKFKARVTF TADTSTSTAY MELSSLRSED TAVYYCARFS 100
HFGSGSNYDYF DYWGQGTIVT VSSASTKGPS VFPLAPSSKS TSGGTAALGC 150
LVKDYFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG 200
TQTYICNVNH KPSNTKVDKK VEPKSCDKTH TCPPCPAPEL LGGSPSVFLFP 250
PKPKDTLMIS RTPEVTCVVV DVSHEDEPEV FNWYVDGVEV HNAKTKPREE 300
QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK TISKAQGQPR 350
EPQVYTLPPS RDELTKNQVS LTCILVKGFPY SDIAVEWESN GQPENNYKTT 400
PFVLDSDGSF FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTKQSLSL 450
PGK 453

```

Light chain / Chaîne légère / Cadena ligera

```

EIVMTQSPAT LSVSPGERAT LSCRASQSIG TNIHWYQKP GQAPRLLIYY 50
ASEISIGIPA RFGSGSGSTE FTLTISSLQS EDFAVYICQQ SWSWPTTFGG 100
GTKVEIKRTV AAPSVFIFFP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSTLT LSKADYERHK VYACEVTHQG 200
LSSPVTKSFN RGEC 214

```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```

Intra-H 22-96 150-206 267-327 373-431
        22'-96" 150"-206" 267"-327" 373"-431"
Intra-L 23'-88' 134'-194'
        23"-88" 134"-194"
Inter-H-L 226-214' 226"-214"
Inter-H-H 232-232" 235-235"

```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
303, 303"

lirilumabum #
lirilumab

immunoglobulin G4-kappa, anti-[*Homo sapiens* KIR2D subgroup (killer cell immunoglobulin-like receptors from KIR2D subgroup including KIR2DL1 (nkat1, CD158A), KIR2DL2 (nkat6, CD158B1), KIR2DL3 (nkat2, CD158B2), KIR2DS1 (CD158H) and KIR2DS2 (nkat5, CD158J)], *Homo sapiens* monoclonal antibody; gamma4 heavy chain (1-450) [*Homo sapiens* VH (IGHV1-69*01 (95.90%) -(IGHD)-IGHJ6*01) [8.8.16] (1-123) -IGHG4*01 hinge S10>P (231) (124-450)], (137-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (98.90%) -IGKJ2*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (229-229":232-232")-bisdisulfide dimer

lirilumab

immunoglobuline G4-kappa, anti-[*Homo sapiens* KIR2D sous-groupe (récepteurs des cellules tueuses du sous-groupe KIR2D appartenant à la superfamille des immunoglobulines et incluant KIR2DL1 (nkat1, CD158A), KIR2DL2 (nkat6, CD158B1), KIR2DL3 (nkat2, CD158B2), KIR2DS1 (CD158H) et KIR2DS2 (nkat5, CD158J)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma4 (1-450) [*Homo sapiens* VH (IGHV1-69*01 (95.90%) -(IGHD)-IGHJ6*01) [8.8.16] (1-123) -IGHG4*01 charnière S10>P (231) (124-450)], (137-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (98.90%) -IGKJ2*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (229-229":232-232")-bisdisulfure

lirilumab

inmunoglobulina G4-kappa, anti-[subgrupo KIR2D de *Homo sapiens* (receptores de células asesinas del subgrupo KIR2D perteneciente a la superfamilia de las inmunoglobulinas y que incluye KIR2DL1 (nkat1, CD158A), KIR2DL2 (nkat6, CD158B1), KIR2DL3 (nkat2, CD158B2), KIR2DS1 (CD158H) et KIR2DS2 (nkat5, CD158J)], anticuerpo monoclonal de *Homo sapiens*; cadena pesada gamma4 (1-450) [*Homo sapiens* VH (IGHV1-69*01 (95.90%) -(IGHD)-IGHJ6*01 [8.8.16] (1-123) -IGHG4*01 bisagra S10>P (231) (124-450)], (137-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (98.90%) -IGKJ2*01 [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (229-229":232-232")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGSSVKV SCKASGGTFS FYAISWVRQA PGQGLEWMGG 50
FIPFIFGAANY AQKFQGRVTI TADESTSTAY MELSSLRSDD TAVYYCARIP 100
SGSYYYDYDM DVWGQGTITV VSSASTKGPS VFPLAPCSRS TSESTAALGC 150
LVKDYFPEFV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG 200
TKTYTCNVHD KPSNTKVDKR VESKYGPFCP PCPAPEFLGG PSVFLFPKP 250
KDTLMISRTP EVTCVVVDVS QEDPEVQFNW YVDGVEVHNA KTKPREEQFN 300
STYRVSVLT VLHQDWLNGK EYKCKVSNKG LPSSIEKTIS KAKGQPREPQ 350
VYTLPPSQEE MTRNQVSLTC LVKGFYPSDI AVEWESNGQF ENNYKTPPV 400
LDSGGSFFLY SRLTVDKSRW QEGNVFSCSV MHEALHNHYT QKSLSLSLGK 450
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPVT LSLSPGERAT LSCRASQSVS SYLAWYQQKQ GPAPRLLIYD 50
ASNRTATGIPA RFGSGSGSDT FTLTISLEP EDFAVYYCQQ RSNWMTYFG 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYLSLSTLT LSKADYEKKH VYACEVTHGQ 200
LSSPVTKSFN RGE 214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H 22-96 150-206 264-324 370-428
        22"-96" 150"-206" 264"-324" 370"-428"
Intra-L 23'-88' 134'-194'
        23"'-88'" 134"'-194'"
Inter-H-L 137-214' 137"-214"
Inter-H-H 229-229" 232-232"
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
300, 300"

lomibuvirum

lomibuvir

5-(3,3-dimethylbut-1-yn-1-yl)-3-((*trans*-4-hydroxycyclohexyl)((*trans*-4-methylcyclohexyl)carbonyl)amino)thiophene-2-carboxylic acid


lomibuvir

acide 5-(3,3-diméthylbut-1-yn-1-yl)-3-((*trans*-4-hydroxycyclohexyl)((*trans*-4-méthylcyclohexyl)carbonyl)amino)thiophène-2-carboxylique

lomibuvir

ácido 5-(3,3-dimetilbut-1-in-1-il)-3-((*trans*-4-hidroxiciclohexil)((*trans*-4-metilciclohexil)carbonil)amino)tiofeno-2-carboxílico

C₂₅H₃₅NO₄S



lucitanibum


lucitanib

6-({7-[(1-aminocyclopropyl)methoxy]-6-methoxyquinolin-4-yl}oxy)-*N*-methylnaphthalene-1-carboxamide

lucitanib

6-({7-[(1-aminocyclopropyl)méthoxy]-6-méthoxyquinoléin-4-yl}oxy)-*N*-méthylnaphtalène-1-carboxamide

lucitanib

6-({7-[(1-aminocyclopropil)metoxi]-6-metoxiquinolin-4-il}oxi)-*N*-metilnaftaleno-1-carboxamidaC₂₆H₂₅N₃O₄**momelotinibum**


momelotinib

N-(cyanomethyl)-4-{2-[4-(morpholin-4-yl)anilino]pyrimidin-4-yl}benzamide

momélotinib

N-(cyanométhyl)-4-{2-[4-(morpholin-4-yl)anilino]pyrimidin-4-yl}benzamide

momelotinib

N-(cianometil)-4-{2-[4-(morfolin-4-il)anilino]pirimidin-4-il}benzamidaC₂₃H₂₂N₆O₂**nivolumabum #**

nivolumab

immunoglobulin G4-kappa, anti-[*Homo sapiens* PDCD1 (programmed cell death 1, PD-1, PD1, CD279)], *Homo sapiens* monoclonal antibody;
 gamma1 heavy chain (1-440) [*Homo sapiens* VH (IGHV3-33*01 (91.80%) -(IGHD)-IGHJ4*01) [8.8.6] (1-113) -IGHG4*01 hinge S10>P (221) (114-440)], (127-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (98.90%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (219-219':222-222'')-bisdisulfide dimer

nivolumab

immunoglobuline G4-kappa, anti-[*Homo sapiens* PDCD1 (protéine 1 de mort cellulaire programmée, PD-1, PD1, CD279)], *Homo sapiens* anticorps monoclonal;
 chaîne lourde gamma1 (1-440) [*Homo sapiens* VH (IGHV3-33*01 (91.80%) -(IGHD)-IGHJ4*01) [8.8.6] (1-113) -IGHG4*01 charnière S10>P (221) (114-440)], (127-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (98.90%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (219-219':222-222'')-bisdisulfure

<

ocaratuzumab

inmunoglobulina G1-kappa, anti-[MS4A1 de *Homo sapiens* (miembro 1 de la subfamilia A de 4 dominios transmembranarios, CD20)], anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-450) [VH humanizado (*Homo sapiens* IGHV5-51*01 (83.70%) -(IGHD)-IGHJ2*01) R120>K (113), L123>T (116) [8.8.14] (1-121) -*Homo sapiens* IGHG1*01 CH2 P11>I (251), A124>Q (343), CHS K2>del (122-450)], (224-213')-disulfuro con la cadena ligera kappa (1'-213') [V-KAPPA humanizado (*Homo sapiens* IGKV3-20*01 (85.40%) -IGKJ2*01) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01 (107'-213')]; dímero (230-230":233-233")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVQSGAE VKKPGESLKI SCRGSGRTFT SYNMHWVRQM PGKGLEWMGA 50
IYPLTGDTSY NQKSKLQVTI SADKSISTAY LQWSSLKASD TAMYYCARST 100
YVGGDWQFDV WKGSTTVTVS SASTKGPSVF PLAPSSKSTS GGTAAALGCLV 150
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ 200
TYICNVNHKP SNTKVDKKVE PKSCDKHTC PPCPAPELLG GPSVFLFPK 250
IKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY 300
NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKQKGQPREP 350
QVYTLPPSRD ELTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTPP 400
VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNNY TQKSLSLSPG 450
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPGT LSLSPGERAT LSCRASSVP YIHWYQQKPG QAPRLLIYAT 50
SALASGIPDR FSGSGSGTDF TLTIISRLPE DFAVYYCQW LSNPPTFGQG 100
TKLEIKRTVA APSVFIFFPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150
NALQSGNSQE SVTEQDSKDS TYSLSTLTSL SKADYEKKV YACEVTHQGL 200
SSPVTKSFNR GEC 213
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H 22"-96" 148"-204" 265"-325" 371"-429"
22"-96" 148"-204" 265"-325" 371"-429"
Intra-L 23"-87" 133"-193"
23"-87" 133"-193"
Inter-H-L 224-213' 224"-213"
Inter-H-H 230-230" 233-233"
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
301, 301"

omarigliptinum

omarigliptin


(2*R*,3*S*,5*R*)-2-(2,5-difluorophenyl)-5-[2-(methanesulfonyl)-4,6-dihydropyrrolo[3,4-*c*]pyrazol-5(2*H*)-yl]oxan-3-amine

omarigliptine

(2*R*,3*S*,5*R*)-2-(2,5-difluorophényl)-5-[2-(méthanesulfonyl)-4,6-dihydropyrrolo[3,4-*c*]pyrazol-5(2*H*)-yl]oxan-3-amine

omarigliptina

(2*R*,3*S*,5*R*)-2-(2,5-difluorofenil)-5-[2-(metanosulfonyl)-4,6-dihidropirrol[3,4-*c*]pirazol-5(2*H*)-il]oxan-3-amina

 $C_{17}H_{20}F_2N_4O_3S$


oprozomibum

oprozomib


O-methyl-N-(2-methyl-1,3-thiazol-5-carbonyl)-L-seryl-O-methyl-N-[(2*S*)-1-[(2*R*)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]-L-serinamide

oprozomib

O-méthyl-N-(2-méthyl-1,3-thiazol-5-carbonyl)-L-séryl-O-méthyl-N-[(2*S*)-1-[(2*R*)-2-méthyloxiran-2-yl]-1-oxo-3-phénylpropan-2-yl]-L-sérinamide

oprozomib

O-metil-N-(2-metil-1,3-tiazol-5-carbonil)-L-seril-O-metil-N-[(2S)-1-[(2R)-2-metiloxiran-2-il]-1-oxo-3-fenilpropan-2-il]-L-serinamida

C₂₅H₃₂N₄O₇Sorticumab #
orticumab

immunoglobulin G1-lambda, anti-[*Homo sapiens* oxLDL (oxidized low-density lipoprotein (LDL), malondialdehyde (MDA)-modified apolipoprotein (apo) B-100)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-451) [*Homo sapiens* VH (IGHV3-23*01 (89.80%) -(IGHD)-IGHJ4*01) [8.8.14] (1-121) -IGHG1*01 (122-451)], (224-215')-disulfide with lambda light chain (1'-216') [*Homo sapiens* V-LAMBDA (IGLV1-47*02 (89.80%) -IGLJ3*02) [8.3.11] (1'-110') -IGLC2*01 (111'-216')]; (230-230'':233-233'')-bisdisulfide dimer

orticumab

immunoglobuline G1-lambda, anti-[*Homo sapiens* oxLDL (lipoprotéine de faible densité (LDL) oxydée, apolipoprotéine (apo) B-100 modifiée par la malondialdéhyde (MDA))], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma1 (1-451) [*Homo sapiens* VH (IGHV3-23*01 (89.80%) -(IGHD)-IGHJ4*01) [8.8.14] (1-121) -IGHG1*01 (122-451)], (224-215')-disulfure avec la chaîne légère lambda (1'-216') [*Homo sapiens* V-LAMBDA (IGLV1-47*02 (89.80%) -IGLJ3*02) [8.3.11] (1'-110') -IGLC2*01 (111'-216')]; dimère (230-230'':233-233'')-bisdisulfure

orticumab

immunoglobulina G1-lambda, anti-[oxLDL de *Homo sapiens* (lipoproteína de baja densidad (LDL) oxidada, apolipoproteína (apo) B-100 modificada por malondialdehído (MDA))], anticuerpo monoclonal de *Homo sapiens*; cadena pesada gamma1 (1-451) [*Homo sapiens* VH (IGHV3-23*01 (89.80%) -(IGHD)-IGHJ4*01) [8.8.14] (1-121) -IGHG1*01 (122-451)], (224-215')-disulfuro con la cadena ligera lambda (1'-216') [*Homo sapiens* V-LAMBDA (IGLV1-47*02 (89.80%) -IGLJ3*02) [8.3.11] (1'-110') -IGLC2*01 (111'-216')]; dímero (230-230'':233-233'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```

EVQLLESGGG LVQPGGSLRL SCAASGFTFS NAWMSWVRQA PGKLEWVSS 50
ISVGGHRTYY ADSVKGRSTI SRDNSKNTLY LQMNSLRAED TAVYCARIR 100
VGPSSGGAFTY WQGGTLTVTS SASTKGPSVF PLAPSSKSTS GGTAAALGCLV 150
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSV TTPSSSLGTQ 200
TYICNVNHKP SNTKVDKKEV PKSCDKTHTC PPCAPELLG GPSVFLFPFK 250
PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY 300
NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP 350
QVYTLPPSRD ELTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTPPP 400
VLDSDGSFFL YSKLTVDKSR WQGNVVFSCS VMHEALHNHY TQKSLSLSPG 450
K 451

```

Light chain / Chaîne légère / Cadena ligera

```

QSVLTQPPSA SGTTPGQRTI SCSSGNTNIG KNYVSWYQQL PGTAPKLLIY 50
ANSNRPSGVP DRFSGSKSGT SASLAISGLR SEDEADYYCA SWDASLNGWV 100
FGGGTKLTVL GQPKAAPSVT LFPPSSSEELQ ANKATLVCLI SDFYPGAVTV 150
AWKADSSPVK AGVETTTPSK QSNNKYAASS YLSLTPEQWK SHRSYSCQVT 200
HEGSTVEKTV APTECS 216

```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 148-204 265-325 371-429
22"-96" 148"-204" 265"-325" 371"-429"

Intra-L 22"-89" 138"-197"
22"-89'" 138'"-197'"

Inter-H-L 224-215' 224"-215"
Inter-H-H 230-230" 233-233"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
301, 301"

parsatuzumabum #

parsatuzumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* EGFL7 (epidermal growth factor (EGF)-like repeat superfamily member 7, EGF-like-domains protein 7)], humanized monoclonal antibody;
gamma1 heavy chain (1-453) [humanized VH (*Homo sapiens*IGHV3-74*01 (80.60%) -(IGHD)-IGHJ6*01 T123>L (118) [8.8.16] (1-123) -*Homo sapiens*IGHG1*03 CH1 R120>K (220) (124-453)], (226-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (*Homo sapiens*IGKV1-39*01 (81.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens*IGKC*01 (113'-219')]; (232-232":235-235")-bisdisulfide dimer

parsatuzumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* EGFL7 (membre 7 de la superfamille des protéines à domaines répétés facteur de croissance épidermique (EGF)-like, protéine 7 à domaines EGF-like)], anticorps monoclonal humanisé;
chaîne lourde gamma1 (1-453) [VH humanisé (*Homo sapiens*IGHV3-74*01 (80.60%) -(IGHD)-IGHJ6*01 T123>L (118) [8.8.16] (1-123) -*Homo sapiens*IGHG1*03 CH1 R120>K (220) (124-453)], (226-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (*Homo sapiens*IGKV1-39*01 (81.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens*IGKC*01 (113'-219')]; dimère (232-232":235-235")-bisdisulfure

parsatuzumab

inmunoglobulina G1-kappa, anti-[EGFL7 de *Homo sapiens* (miembro 7 de la superfamilia de proteínas de dominios repetidos factor de crecimiento epidérmico (EGF)-like, proteína 7 de dominios EGF-like)], anticuerpo monoclonal humanizado;
cadena pesada gamma1 (1-453) [VH humanizada (*Homo sapiens*IGHV3-74*01 (80.60%) -(IGHD)-IGHJ6*01 T123>L (118) [8.8.16] (1-123) -*Homo sapiens*IGHG1*03 CH1 R120>K (220) (124-453)], (226-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizada (*Homo sapiens*IGKV1-39*01 (81.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens*IGKC*01 (113'-219')]; dímero (232-232":235-235")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

EVQLVESGGG	LVQPGGSLRL	SCAASGYTFI	DYYMNWVRQA	PGKGLEWVGD	50
INLDNSGTHY	NQKFKGRFTI	SRDKSKNTAY	LQMNSLRAED	TAVYYCAREG	100
VYHDYDDYAM	DYWGQGTIVT	VSSASTKGPS	VFPLAPSSKS	TSGGTAALGC	150
LVKDYFPEPEV	TVSWNSGALT	SGVHTFPAVL	QSSGLYSLSS	VVTVPSSSLG	200
TQTYICNVNH	KPSNTKVDKK	VEPKSCDKTH	TCPPCPAPEL	LGGPSVFLFP	250
FKPKDTLMIS	RTPEVTCVVV	DVSHEDPEVK	FNWYVDGVEV	HNAKTKPREE	300
QYNSTYRVVS	VLTVLHQDWL	NGKEYKCKVS	NKALPAPIEK	TISKAKGQPR	350
EPQVYTLPPS	REEMTKNQVS	LTCLVKGFYP	SDIAVEWESN	GQPENNYKTT	400
PPVLDSDGSF	FLYSKLTVDK	SRWQQGNVFS	CSVMHEALHN	HYTQKSLSL	450
PGK					453

Light chain / Chaîne légère / Cadena ligera

DIQMTQSPSS	LSASVGDRVT	ITCRTSQSLV	HINAIYTLHW	YQQKFGKAPK	50
LLIYRVSNRF	SGVPSRFSGS	GSGETFTLTI	SSLQPEDFAT	YYCGQSTHVP	100
LTFGQGTKEV	IKRTVAAPSV	FIFPPSDEQL	KSGTASVVCL	LNNFYPREAK	150
VQWKVDNALQ	SGNSQESVTE	QDSKDSITYSL	SSTLTLSKAD	YEKHKVYACE	200
VTHQGLSSPV	TKSFNRGEC				219

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H	22-96	150-206	267-327	373-431
	22"-96"	150"-206"	267"-327"	373"-431"
Intra-L	23'-93'	139'-199'		
	23'''-93'''	139'''-199'''		
Inter-H-L	226-219'	226"-219'"		
Inter-H-H	232-232"	235-235"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
303, 303"

pefcalcitolum

pefcalcitol


2-[[[(1*S*,3*R*,5*Z*,7*E*,20*S*)-1,3-dihydroxy-9,10-secopregna-5,7,10(19),16-tetraen-20-yl]oxy]-*N*-(2,2,3,3,3-pentafluoropropyl)acetamide

pefcalcitol

2-[[[(1*S*,3*R*,5*Z*,7*E*,20*S*)-1,3-dihydroxy-9,10-secopregna-5,7,10(19),16-tetraen-20-yl]oxy]-*N*-(2,2,3,3,3-pentafluoropropyl)acétamide

pefcalcitol

2-[[[(1*S*,3*R*,5*Z*,7*E*,20*S*)-1,3-dihidroxi-9,10-secopregna-5,7,10(19),16-tetraen-20-il]oxi]-*N*-(2,2,3,3,3-pentafluoropropil)acetamida

C₂₆H₃₄F₅NO₄**perakizumabum #**

perakizumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* IL17A (interleukin 17A, IL-17A)], humanized monoclonal antibody; gamma1 heavy chain (1-452) [humanized VH (*Homo sapiens* IGHV3-7*01 (90.80%) -(IGHD)-IGHJ4*01) [8.8.15] (1-122) -*Homo sapiens* IGHG1*01 CH2 L1.3>A (239), L1.2>A (240) (123-452)], (225-215')-disulfide with kappa light chain (1'-215') [humanized V-KAPPA (*Homo sapiens* IGKV1-16*01 (82.10%) -IGKJ2*01) [6.3.10] (1'-108') -*Homo sapiens* IGKC*01 (109'-215')]; (231-231":234-234")-bisdisulfide dimer

pérakizumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* IL17A (interleukine 17A, IL-17A)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-452) [VH humanisé (*Homo sapiens* IGHV3-7*01 (90.80%) -(IGHD)-IGHJ4*01) [8.8.15] (1-122) -*Homo sapiens* IGHG1*01 CH2 L1.3>A (239), L1.2>A (240) (123-452)], (225-215')-disulfure avec la chaîne légère kappa (1'-215') [V-KAPPA humanisé (*Homo sapiens* IGKV1-16*01 (82.10%) -IGKJ2*01) [6.3.10] (1'-108') -*Homo sapiens* IGKC*01 (109'-215')]; dimère (231-231":234-234")-bisdisulfure

perakizumab

inmunoglobulina G1-kappa, anti-[IL17A de *Homo sapiens* (interleukina 17A, IL-17A)], anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-452) [VH humanizado (*Homo sapiens* IGHV3-7*01 (90.80%) -(IGHD)-IGHJ4*01) [8.8.15] (1-122) -*Homo sapiens* IGHG1*01 CH2 L1.3>A (239), L1.2>A (240) (123-452)], (225-215')-disulfuro con la cadena ligera kappa (1'-215') [V-KAPPA humanizado (*Homo sapiens* IGKV1-16*01 (82.10%) -IGKJ2*01) [6.3.10] (1'-108') -*Homo sapiens* IGKC*01 (109'-215')]; dímero (231-231":234-234")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```

EVQLVESGGG LVQPGGSLRL SCAASGFTFS DYTMLWVRQA PGKGLEWVAI 50
IKSGGSYSYY PDSVKGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCARDG 100
DYGSSYGAMD YWGQGTLLTVV SSASTKGPSV FPLAPSSKST SGGTAALGCL 150
VKDYFFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTPSSSLSGT 200
QTYICNVNHK PSNTKVDKKV EPKSCDKTHT CPPCPAPEAA GGPSVFLFPP 250
KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ 300
YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KALPAPIEKI ISKAKGQPRE 350
PQVYTLPPSR DELTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTFP 400
FVLDSGDSFF LYSKLTVDKS RWQQGNVFSV SVMHEALHNN YTQKSLSLSP 450
GK 452

```

Light chain / Chaîne légère / Cadena ligera

```

DIQMTQSPSS LSASVGDRVT ITCRASQDIN SYLSWFQQKP GKAPKSLIVR 50
ANRLVDGVPS RFGSGSGGQD YSLTISSLQP EDFATYYCLQ YDAFFPYTFG 100
QGTKLEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYLSSTL TSKADYEKH KKYACEVTHQ 200
GLSSPVTKSF NRGEK 215

```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 149-205 266-326 372-430
 22"-96" 149"-205" 266"-326" 372"-430"

Intra-L 23"-88" 135"-195"

23"-88" 135"-195"

Inter-H-L 225-215' 225"-215"

Inter-H-H 231-231" 234-234"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
 302, 302"

pictilisibum

pictilisib

2-{1*H*-indazol-4-yl}-6-[[4-(methanesulfonyl)piperazin-1-yl]methyl]-
 4-(morpholin-4-yl)thieno[3,2-*d*]pyrimidine


pictilisib

2-(1*H*-indazol-4-yl)-6-[[4-(méthanesulfonyl)pipérazin-1-yl]méthyl]-
 4-(morpholin-4-yl)-thiéno[3,2-*d*]pyrimidine

pictilisib


2-{1*H*-indazol-4-il}-6-[[4-(metanosulfoniil)piperazin-1-il]metil]-
 4-(morfolin-4-il)tiéno[3,2-*d*]pirimidina

C₂₃H₂₇N₇O₃S₂

**placulumabum #**


placulumab

immunoglobulin (V-kappa)2-Fc gamma1, anti-[*Homo sapiens* TNF (tumor necrosis factor, TNF superfamily member 2, TNFSF2, TNF-alpha, TNFA)], *Homo sapiens* monoclonal antibody;
 V-kappa -(CH1>del) gamma1 chain (1-341) [*Homo sapiens* V-KAPPA (IGKV1-39*01 (87.40%) -IGKJ1*01) [6.3.9] (1-107) -IGHG1*01 [CH1 1.4-119>del, K120>R (108) (108-109), hinge 1-15 C5>S (114) (110-124), CH2 (125-234), CH3 (235-339), CHS (340-341)]; (120-120':123-123')-bisdisulfide dimer

placulumab	immunoglobuline (V-kappa)2-Fc gamma1, anti-[<i>Homo sapiens</i> TNF (facteur de nécrose tumorale, membre 2 de la superfamille du TNF, TNFSF2, TNF-alpha, TNFA)], <i>Homo sapiens</i> anticorps monoclonal; chaîne V-kappa -(CH1>del) gamma1 (1-341) [<i>Homo sapiens</i> V-KAPPA (IGKV1-39*01 (87.40%) -IGKJ1*01) [6.3.9] (1-107) -IGHG1*01 [CH1 1.4-119>del, K120>R (108) (108-109), charnière 1-15 C5>S (114) (110-124), CH2 (125-234), CH3 (235-339), CHS (340-341)]; dimère (120-120':123-123')-bisdisulfure																																																						
placulumab	<p>inmunoglobulina (V-kappa)2-Fc gamma1, anti-[TNF de <i>Homo sapiens</i> (factor de necrosis tumoral, miembro 2 de la superfamilia del TNF, TNFSF2, TNF-alfa, TNFA)], anticuerpo monoclonal de <i>Homo sapiens</i>;</p> <p>cadena V-kappa -(CH1>del) gamma1 (1-341) [<i>Homo sapiens</i> V-KAPPA (IGKV1-39*01 (87.40%) -IGKJ1*01) [6.3.9] (1-107) -IGHG1*01 [CH1 1.4-119>del, K120>R (108) (108-109), bisagra 1-15 C5>S (114) (110-124), CH2 (125-234), CH3 (235-339), CHS (340-341)]; dímero (120-120':123-123')-bisdisulfuro</p> <p>Heavy chain / Chaîne lourde / Cadena pesada</p> <table><tr><td>DIQMTQSPSS</td><td>LSASVGDRTV</td><td>ITCRASQAID</td><td>SYLHWYQQKP</td><td>GKAPKLLIYS</td><td>50</td></tr><tr><td>ASNLETGVPS</td><td>RFGSGSGGTD</td><td>FTLTISLLP</td><td>EDFATYYCQQ</td><td>VVWRPFTFGQ</td><td>100</td></tr><tr><td>GTKVEIKRVE</td><td>PKSSDKHTC</td><td>PPCPAPELLG</td><td>GPSVFLFPPK</td><td>PKDTLMISRT</td><td>150</td></tr><tr><td>PEVTCVVVDV</td><td>SHEDPEVKFN</td><td>WYVDGVEVHN</td><td>AKTKPREEQY</td><td>NSTYRVVSVL</td><td>200</td></tr><tr><td>TVLHQDWLNG</td><td>KEYKCKVSNK</td><td>ALPAPIEKTI</td><td>SKAKGQPREP</td><td>QVYTLPPSRD</td><td>250</td></tr><tr><td>ELTKNQVSLT</td><td>CLVKGFYPSD</td><td>IAVEWESNGQ</td><td>PENNYKTTTP</td><td>VLDSDGSEFFL</td><td>300</td></tr><tr><td>YSKLTVDKSR</td><td>WQQGNVFSCS</td><td>VMHEALHNHY</td><td>TQKSLSLSPG</td><td>K</td><td>341</td></tr></table> <p>Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro</p> <table><tr><td>Intra-H</td><td>23-88</td><td>155-215</td><td>261-319</td></tr><tr><td></td><td>23'-88'</td><td>155'-215'</td><td>261'-319'</td></tr><tr><td>Inter-H-H</td><td>120-120'</td><td>123-123'</td><td></td></tr></table> <p>N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación</p> <p>H CH2 N84.4: 191, 191'</p>	DIQMTQSPSS	LSASVGDRTV	ITCRASQAID	SYLHWYQQKP	GKAPKLLIYS	50	ASNLETGVPS	RFGSGSGGTD	FTLTISLLP	EDFATYYCQQ	VVWRPFTFGQ	100	GTKVEIKRVE	PKSSDKHTC	PPCPAPELLG	GPSVFLFPPK	PKDTLMISRT	150	PEVTCVVVDV	SHEDPEVKFN	WYVDGVEVHN	AKTKPREEQY	NSTYRVVSVL	200	TVLHQDWLNG	KEYKCKVSNK	ALPAPIEKTI	SKAKGQPREP	QVYTLPPSRD	250	ELTKNQVSLT	CLVKGFYPSD	IAVEWESNGQ	PENNYKTTTP	VLDSDGSEFFL	300	YSKLTVDKSR	WQQGNVFSCS	VMHEALHNHY	TQKSLSLSPG	K	341	Intra-H	23-88	155-215	261-319		23'-88'	155'-215'	261'-319'	Inter-H-H	120-120'	123-123'	
DIQMTQSPSS	LSASVGDRTV	ITCRASQAID	SYLHWYQQKP	GKAPKLLIYS	50																																																		
ASNLETGVPS	RFGSGSGGTD	FTLTISLLP	EDFATYYCQQ	VVWRPFTFGQ	100																																																		
GTKVEIKRVE	PKSSDKHTC	PPCPAPELLG	GPSVFLFPPK	PKDTLMISRT	150																																																		
PEVTCVVVDV	SHEDPEVKFN	WYVDGVEVHN	AKTKPREEQY	NSTYRVVSVL	200																																																		
TVLHQDWLNG	KEYKCKVSNK	ALPAPIEKTI	SKAKGQPREP	QVYTLPPSRD	250																																																		
ELTKNQVSLT	CLVKGFYPSD	IAVEWESNGQ	PENNYKTTTP	VLDSDGSEFFL	300																																																		
YSKLTVDKSR	WQQGNVFSCS	VMHEALHNHY	TQKSLSLSPG	K	341																																																		
Intra-H	23-88	155-215	261-319																																																				
	23'-88'	155'-215'	261'-319'																																																				
Inter-H-H	120-120'	123-123'																																																					
pocapavirum pocapavir	1,3-dichloro-2-({4-[(2-chloro-4-methoxyphenoxy)methyl]phenyl}methoxy)benzene																																																						
pocapavir	1,3-dichloro-2-({4-[(2-chloro-4-méthoxyphénoxy)méthyl]phényl}méthoxy)benzene																																																						
pocapavir	1,3-dicloro-2-({4-[(2-cloro-4-metoxifenoxi)metil]fenil}metoxi)benceno																																																						
	<p>C₂₁H₁₇Cl₃O₃</p> 																																																						
pradimotidum pradimotide	human vascular endothelial growth factor receptor 1 (VEGFR-1)-(1058-1066)-peptide																																																						
pradimotide	récepteur 1 du facteur de croissance de l'endothélium vasculaire humain (VEGFR-1)-(1058-1066)-peptide																																																						
pradimotida	receptor 1 del factor de crecimiento endotelial vascular humano (VEGFR-1)-(1058-1066)-péptido																																																						

quisinostat

quisinostat





N-hydroxy-2-[4-({[(1-methyl-1*H*-indol-3-yl)methyl]amino)methyl]piperidin-1-yl]pyrimidine-5-carboxamide

quisinostat

N-hydroxy-2-[4-({[(1-méthyl-1*H*-indol-3-yl)méthyl]amino)méthyl]pipéridin-1-yl]pyrimidine-5-carboxamide

quisinostat

N-hidroxi-2-[4-({[(1-metil-1*H*-indol-3-il)metil]amino)metil]piperidin-1-il]pirimidina-5-carboxamida

**rabusertibum**

rabusertib


1-(2-chloro-3-fluorophenyl)-3-[4-chloro-2-hydroxy-3-(piperazine-1-sulfonyl)phenyl]urea

rabusertib

1-(5-bromo-4-méthyl-2-{{(2*S*)-morpholin-2-yl}méthoxy}phényl)-3-(5-méthylpyrazin-2-yl)urée

rabusertib

1-(2-cloro-3-fluorofenil)-3-[4-cloro-2-hidroxi-3-(piperazina-1-sulfonyl)fenil]urea

**relugolixum**

relugolix



1-(4-{1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl}phenyl)-3-methoxyurea

rélugolix

1-(4-{1-[(2,6-difluorophényl)méthyl]-5-[(diméthylamino)méthyl]-3-(6-méthoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tétrahydrothiéno[2,3-d]pyrimidin-6-yl}phényl)-3-méthoxyurea

relugolix

1-(4-{1-[(2,6-difluorofenil)metil]-5-[(dimetilamino)metil]-3-(6-metoxipiridazin-3-il)-2,4-dioxo-1,2,3,4-tetrahidrotieno[2,3-d]pirimidin-6-il}fenil)-3-metoxiurea



rilimogenum galvacirepvecum #
rilimogene galvacirepvec

recombinant replicating vaccinia viral vector expressing a modified prostate specific antigen (PSA) plus three co-stimulatory molecules, lymphocyte associated function antigen-3 (LFA-3), intracellular adhesion molecule-1 (ICAM-1) and B7.1.

rilimogène galvacirépvec

vecteur viral recombinant de la vaccine répliquant exprimant un antigène modifié spécifique de la prostate et trois protéines co-stimulantes (antigène 3 associé aux fonctions lymphocytaires (LFA-3), molécule d'adhésion intracellulaire-1 (ICAM-1) et B7.1)

rilimogén galvacirepvec

vector viral recombinante de la vacuna replicante que expresa un antígeno modificado específico prostático y tres proteínas co-stimulantes (antígeno 3 asociado a las funciones limfocitarias (LFA-3), molécula d'adhesión intracelular-1 (ICAM-1) y B7.1)

rilimogenum glafolivecum #
rilimogene glafolivec

recombinant non-replicating fowlpox viral vector expressing a modified prostate specific antigen (PSA) plus three co-stimulatory molecules, lymphocyte associated function antigen-3 (LFA-3), intracellular adhesion molecule-1 (ICAM-1) and B7.1

rilimogène glafolivec

vecteur viral recombinant non-répliquant de la variole aviaire exprimant un antigène modifié spécifique de la prostate et trois protéines co-stimulantes (antigène 3 associé aux fonctions lymphocytaires (LFA-3), molécule d'adhésion intracellulaire-1 (ICAM-1) et B7.1)

rilimogén glafolivec

vector viral recombinante no-replicante de la viruela aviar que expresa un antígeno modificado específico prostático y tres proteínas co-stimulantes (antígeno 3 asociado a las funciones limfocitarias (LFA-3), molécula d'adhesión intracelular-1 (ICAM-1) y B7.1)

rovatirelinum
rovatirelin


(4*S*,5*S*)-5-methyl-*N*-{(2*S*)-1-[(2*R*)-2-methylpyrrolidin-1-yl]-1-oxo-3-[(1,3-thiazol-4-yl)methyl]propan-2-yl}-2-oxo-1,3-oxazolidine-4-carboxamide

rovatiréline

(4*S*,5*S*)-5-méthyl-*N*-{(2*S*)-1-[(2*R*)-2-méthylpyrrolidin-1-yl]-1-oxo-3-[(1,3-thiazol-4-yl)méthyl]propan-2-yl}-2-oxo-1,3-oxazolidine-4-carboxamide

rovatirelina

4*S*,5*S*)-5-méthyl-*N*-[(2*S*)-1-[(2*R*)-2-méthylpyrrolidin-1-yl]-1-oxo-3-[(1,3-tiazol-4-yl)méthyl]propan-2-yl]-2-oxo-1,3-oxazolidine-4-carboxamide

C₁₆H₂₂N₄O₄S

sebelipasum alfa #
sebelipase alfa

human lysosomal acid lipase/cholesteryl ester hydrolase (cholesteryl esterase, lipase A, EC=3.1.1.13) glycosylated (produced in transgenic *Gallus*)

sébelipase alfa

lipase acide lysosomale/hydrolase d'esters de cholesteryl (cholestéryl estérase, lipase A, EC=3.1.1.13), enzyme humaine glycosylée produite par *Gallus* transgénique

sebelipasa alfa

lipasa ácida lisosómica/hidrolasa de los ésteres de colesterol (colesteril esterasa, lipasa A, EC=3.1.1.13), enzima humana glicosilada producida por *Gallus* transgénico

```
SGGKLTAVDP  ETNMNVSEII  SYWGFPSSEY  LVETEDGYIL  CLNRIPHGRK  50
NHSDKGPKEV  VFLQHGLLAD  SSNWVTNLAN  SSLGFILADA  GFDVWMGNSR  100
GNTWSRKHKR  LSVSQDEFWA  FSYDEMAKYD  LPASINFILN  KTGQEQVYV  150
GHSQGTIGIF  IAFSQIPELA  KRIKMFFALG  PVASVAFCTS  PMAKLGRLPD  200
HLIKDLFGDK  EFLPQSAFLK  WLGTHTVCTH  ILKELCGNLC  FLLCGFNERN  250
LNMSRVDVYT  THSPAGTSVQ  NMLHWSQAVK  FQKFQAFDWG  SSARNYFHYN  300
QSYPTYNVK  DMLVPTAVWS  GGHDLWLDVY  DVNILLTQIT  NLVFHESIPE  350
WEHLDFIWGL  DAPWRLYNKI  INLMRKYQ  378
```

Disulfide bridges location* / Positions* des ponts disulfure / Posiciones* de los puentes disulfuro
41-188 227-236 240-244

* predicted / prévues / previstas

Glycosylation sites (N) / sites de glycosylation (N) / posiciones de glicosilación (N)
Asn-15 Asn-80 Asn-140 Asn-252 Asn-300

senrebotasum #
senrebotase

L-methionylglycyl-L-seryl-des-(445-glycine,446-L-tyrosine)-[2-L-glutamic acid,432,442,444,447-tetra- L-aspartic acid]botulinum neurotoxin A precursor 27-L-alanine variant light chain (433-41')-disulfide with [14-L-arginine,15-L-lysine]human nociceptin fusion protein with L-alanyl-L-leucyl-L-alanyltris(tetraglycyl-L-seryl)-[3-L-valine,4-L-leucine,5-L-glutamine-418-L-leucine,419-L-aspartic acid]botulinum neurotoxin A heavy chain-(1-419)-peptide

senrébotase

L-méthionylglycyl-L-séryl-dès-(445-glycine,446-L-tyrosine)-[2-L-acide glutamique,432,442,444,447-tétra-L-acide aspartique]chaîne légère du 27-L-alanine-variant du précurseur de la neurotoxine A botulique (433-41')-disulfure avec le [14-L-arginine,15-L-lysine]nociceptine humaine protéine de fusion avec le L-alanyl-L-leucyl-L-alanyltris(tétraglycyl-L-seryl)-[3-L-valine,4-L-leucine,5-L-glutamine-418-L-leucine,419-L-acide aspartique]chaîne lourde de la neurotoxine A botulique-(1-419)-peptide

senrebotasa

L-metionilglicil-L-seril-des-(445-glicina,446-L-tirosina)-[2-L-ácido glutámico,432,442,444,447-tetra-L-ácido aspártico]cadena ligera de la 27-L-alanina-variante del precursor de la neurotoxina botulínica A (433-41')-disulfuro con la [14-L-arginina,15-L-lisina]nociceptina humana proteína de fusión con el L-alanil-L-leucil-L-alaniltris(tetraglicil-L-seril)-[3-L-valina,4-L-leucina,5-L-glutamina-418-L-leucina,419-L-ácido aspártico]cadena pesada de la neurotoxina botulínica A-(1-419)-péptido

Light chain / Chaîne légère / Cadena ligera		
MGSMEFVNKQ	FNKQDPVNGV	DIAYIKIPNA GQMOPVKAFK IHNKIWIPIE 50
RDTFTNPEEG	DLNPPPEAKQ	VPVSYDYDSTY LSTDNEKDNY LKGVTKLFER 100
IYSTDLGRML	LTSIVRGIPF	WGGSTIDTEL KVIDTNCINV IQPDGGSYRSE 150
ELNLVIIGPS	ADIIQFECKS	FGHEVLNLTR NGYGSTQYIR FSPDFTFGFE 200
ESLEVDTNPL	LGAGKFATDP	AVTLAHELIIH AGHRLYGIAI NPNRVFKVNT 250
NAYYEMSGLE	VSFEELRTFG	GHDAKFIDSL QENEFRLYYY NKFKDIASATL 300
NKAKSIVGTT	ASLQYMKNVF	KEKYLLSEDT SGKFSVDKLE FDKLYKMLTE 350
IYTEDNEVKE	FKVLNRKTYL	NFDKAVFKIN IVPKVNYTIY DGFNLRLNTNL 400
AANFNGQNT	INNMNFTKLK	NFTGLFEFYK LLCVDGIITS KTKSDDDDK 449
Heavy chain / Chaîne lourde / Cadena pesada		
FGGFTGARKS	ARKRKNQALA	GGGSGGGGGS GGGGSALVLQ CIKVNNDWLF 50'
FSPSEDNFTN	DLNKGEEITS	DTNIEAAEEN ISLDLIQQYY LTFNFDNEPE 100'
NISIEENLSSD	IIGQLELMPN	IERFPNGKKY ELDKYTMFHY LRAQEFEGHK 150'
SRIALTNSVN	EALLNPSRVY	TFFSSDYVKK VNKATEAAMF LGWVEQLVVD 200'
FTDETSEVST	TDKIADITII	IPYIGPALNI GNMLYKDDFV GALIFSGAVI 250'
LLEFIPEIAI	PVLGTFALVS	YIANKVLTVO TIDNALSERN EKWDEVYKYI 300'
VTNWLAKVNT	QIDLIRKKMK	EALFNQAEAT KATINYQYNQ YTEEEKNNIN 350'
FNIDDLSSKL	NESINKAMIN	INKFLNQCSV SYLMNSMIPY GVKRLDFDA 400'
SLKDALLKYI	YDNRGTLIGQ	VDRLKDKVNN TLSTDIPFQL SKYVDNQRL 450'
STLD		454'

Disulfide bridge location / Position du pont disulfure / Posición del puente disulfuro 433-41'

sepranolonum
sepranolone

3β-hydroxy-5α-pregnan-20-one


sépranolone

3β-hydroxy-5α-prégnan-20-one

sepranolona

3β-hidroxi-5α-pregnan-20-ona

C₂₁H₃₄O₂



simtuzumabum #
simtuzumab

immunoglobulin G4-kappa, anti-[*Homo sapiens* LOXL2 (lysyl oxidase-like 2)], humanized monoclonal antibody; gamma4 heavy chain (1-443) [humanized VH (*Homo sapiens* IGHV1-2*02 (80.60%) -(IGHD)-IGHJ4*01 L123>T (111) [8.8.9] (1-116) -*Homo sapiens* IGHG4*01 hinge S10>P (224) (117-443)], (130-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (*Homo sapiens* IGKV2D-29*02 (86.00%) -IGKJ4*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; (222-222'':225-225'')-bisdisulfide dimer

simtuzumab immunoglobuline G4-kappa, anti-[*Homo sapiens* LOXL2 (protéine 2 lysyl oxydase-like)], anticorps monoclonal humanisé; chaîne lourde gamma4 (1-443) [VH humanisé (*Homo sapiens*IGHV1-2*02 (80.60%) -(IGHD)-IGHJ4*01 L123>T (111) [8.8.9] (1-116) -*Homo sapiens*IGHG4*01 charnière S10>P (224) (117-443)], (130-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (*Homo sapiens*IGKV2D-29*02 (86.00%) -IGKJ4*01) [11.3.9] (1'-112') -*Homo sapiens*IGKC*01 (113'-219')]; dimère (222-222":225-225")-bisdisulfure

simtuzumab inmunoglobulina G4-kappa, anti-[LOXL2 de *Homo sapiens* (lysyl oxydase-like 2)], anticuerpo monoclonal humanizado; cadena pesada gamma4 (1-443) [VH humanizado (*Homo sapiens*IGHV1-2*02 (80.60%) -(IGHD)-IGHJ4*01 L123>T (111) [8.8.9] (1-116) -*Homo sapiens*IGHG4*01 bisagra S10>P (224) (117-443)], (130-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizado (*Homo sapiens*IGKV2D-29*02 (86.00%) -IGKJ4*01) [11.3.9] (1'-112') -*Homo sapiens*IGKC*01 (113'-219')]; dímero (222-222":225-225")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGASVKV SCKASGYFT YYLIEWVRQA PGQGLEWIGV 50
INPGSGGTNY NEKFKGRATI TADKSTSTAY MELSSLRSRD TAVYFCARNW 100
MNFDFYWGQGT TVTVSSASTK GPSVFPPLAPC SRSTSESTAA LGCLVKDYFPP 150
EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS SLGKTKYTCN 200
VDHKPSNTKV DKRVESKYGK PCPPCPAPEF LGGFSVFLFP PKPKDTLMIS 250
RTPEVTCVVV DVSQEDPEVK FNWYVDGVEV HNAKTKPREE QFNSTYRVVS 300
VLTVLHQDWL NGKEYKCKVS NKGLPSSIEK TISKAKGQPR EPQVYTLPPS 350
QEEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT PPVLDSDGSF 400
FLYSRLTVDK SRWQEGNVFS CSVMHEALHN HYTKSLSL LSK 443
```

Light chain / Chaîne légère / Cadena ligera

```
DIVMTQTPLS LSVTPGQPAS ISCRSSKSL LHSNGNTYLYW FLQKPGQSPQ 50
FLIYRMSNLA SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCMQHLEYP 100
YTFGGGKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVC LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNREGC 219
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 143-199 257-317 363-421
 22"-96" 143"-199" 257"-317" 363"-421"
 Intra-L 23'-93' 139'-199'
 23'''-93''' 139'''-199'''
 Inter-H-L 130-219' 130"-219"
 Inter-H-H 222-222" 225-225"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
 H CH2 N84.4:
 293, 293"

sonidegibum

sonidegib



N-{6-[(2*R*,6*S*)-2,6-dimethylmorpholin-4-yl]pyridin-3-yl}-2-methyl-4'-(trifluoromethoxy)-[1,1'-biphenyl]-3-carboxamide

sonidéigib

N-{6-[(2*R*,6*S*)-2,6-diméthylmorpholin-4-yl]pyridin-3-yl}-2-méthyl-4'-(trifluorométhoxy)-[1,1'-biphényl]-3-carboxamide

sonidegib

N-{6-[(2*R*,6*S*)-2,6-dimetilmorfolin-4-il]piridin-3-il}-2-metil-4'-(trifluorometoxi)-[1,1'-bifenil]-3-carboxamida

**sonolisibum**

sonolisib



(4*E*)-4-[[[bis(prop-2-en-1-yl)amino]methylidene]-6-hydroxy-1α-(methoxymethyl)-3,7,17-trioxo-2-oxaandrost-5,8-dien-11α-yl] acetate

sonolisib

acétate de (4*E*)-4-[[[bis(prop-2-én-1-yl)amino]méthylidène]-6-hydroxy-1α-(méthoxyméthyl)-3,7,17-trioxo-2-oxaandrost-5,8-diène-11α-yle

sonolisib

acetato de (4*E*)-4-[[[bis(prop-2-en-1-il)amino]metilideno]-6-hidroxi-1α-(metoximetil)-3,7,17-trioxo-2-oxaandrost-5,8-dien-11α-ilo

**surotomycinum**

surotomycin



N-[[(2*E*)-3-(4-pentylphenyl)but-2-enoyl]-L-tryptophyl-D-asparaginyl-L-α-aspartyl-L-threonylglycyl-L-ornithyl-L-α-aspartyl-D-alanyl-L-α-aspartylglycyl-D-seryl-(3*R*)-3-methyl-L-α-glutamyl-3-(2-aminobenzoyl)-L-alanine 13→4-lactone

surotomycine

N-[(2*E*)-3-(4-pentylphényl)but-2-énoyl]-L-tryptophyl-D-asparaginyl-L-α-aspartyl-L-thréonylglycyl-L-ornithyl-L-α-aspartyl-D-alanyl-L-α-aspartylglycyl-D-séryl-(3*R*)-3-méthyl-L-α-glutamyl-3-(2-aminobenzoyl)-L-alanine 13→4-lactone

surotomicina

N-[(2*E*)-3-(4-pentilfenil)but-2-enoil]-L-triptofil-D-asparaginil-L-α-aspartil-L-treonilglicil-L-ornitil-L-α-aspartil-D-alanil-L-α-aspartilglicil-D-seril-(3*R*)-3-metil-L-α-glutamil-3-(2-aminobenzoil)-L-alanina 13→4-lactona



technetium (^{99m}Tc) etarfolatidum
technetium (^{99m}Tc) etarfolatide

(SPY-5-24)-[N^2 -(4-[[[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino]benzoyl)-D- γ -glutamyl-(2S)-2-(amino- κN)- β -alanyl-L- α -aspartyl- κN -L-cysteinato- $\kappa N, \kappa S$]oxido[^{99m}Tc]technetate


technétium (^{99m}Tc) étarfolatide

(SPY-5-24)-[N^2 -(4-[[[(2-amino-4-oxo-1,4-dihydroptéridin-6-yl)méthyl]amino]benzoïl)-D- γ -glutamyl-(2S)-2-(amino- κN)- β -alanil-L- α -aspartil- κN -L-cystéinato- $\kappa N, \kappa S$]oxido[^{99m}Tc]technétate

tecnecio (^{99m}Tc) etarfolatida

(SPY-5-24)-[N^2 -(4-[[[(2-amino-4-oxo-1,4-dihydropteridin-6-il)metil]amino]benzoil)-D- γ -glutamyl-(2S)-2-(amino- κN)- β -alanil-L- α -aspartil- κN -L-cisteinato- $\kappa N, \kappa S$]oxido[^{99m}Tc]tecnecetato

$\text{C}_{29}\text{H}_{32}\text{N}_{11}\text{O}_{12}\text{STc}$



tenapanorum
tenapanor

N,N'-(10,17,-dioxo-3,6,21,24-tetraoxa-9,11,16,18-tetraazahexacosane-1,26-diyl)bis[[(4S)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl]benzenesulfonamide}


ténapanor

N,N'-(10,17,-dioxo-3,6,21,24-tétraoxa-9,11,16,18-tétraazahexacosane-1,26-diyl)bis[[(4S)-6,8-dichloro-2-méthyl-1,2,3,4-tétrahydroisoquinoléin-4-yl]benzènesulfonamide}

tenapanor

N,N'-(10,17,-dioxo-3,6,21,24-tetraoxa-9,11,16,18-tetraazahexacosano-1,26-diol)bis[[(4S)-6,8-dicloro-2-metil-1,2,3,4-tetrahydroisoquinolin-4-il]bencenosulfonamida}

$\text{C}_{50}\text{H}_{66}\text{Cl}_4\text{N}_8\text{O}_{10}\text{S}_2$



trabodenosonum
trabodenoson



N^6 -cyclopentyladenosine 5'-nitrate

trabodénoson

5'-nitrate de N^6 -cyclopentyladénosine

trabodenosón

5'-nitrato de N^6 -ciclopentiladenosina



trempamotidum
trempamotide



human kinesin like protein KIF20B (M phase phosphoprotein 1)-(278-286)-peptide

trempamotide

membre 20B des protéines de la famille des kinésines humaines (phosphoprotéine 1 de la phase M)-(278-286)-peptide

trempamotida

miembro 20B de las proteínas de la familia de las kinesinas humanas (fosfoproteína 1 de la fase M)-(278-286)-péptido



trenonacogum alfa #
trenonacog alfa

human coagulation factor IX (EC 3.4.21.22, Christmas factor, plasma thromboplastin component), 148-threonine variant, produced in Chinese Hamster Ovary (CHO) cells (alfa glycoform)

trénonacog alfa

variant 148-thréonine du facteur IX humain de coagulation (EC 3.4.21.22, facteur Christmas, facteur antihémophilique B) produit par culture de cellules ovariennes de hamster chinois (CHO) (glycoforme alfa)

trenonacog alfa

148-treonina-variante del factor IX humano de la coagulación sanguínea (EC 3.4.21.22, factor Christmas, factor antihemofílico B) producido por cultivo de células ováricas de hamster chinos (CHO) (glicoforma alfa)

```


YNSGKLEEFV QGNLERECME EKCSFEEARE VFENTERTTE FWKQYVDGDQ 50
CESNPCLNGG SKDDINSYE CWCPFGFEGK NCELDVTCNI KNGRCEQFCK 100
NSADNKVVCS CTEGYRLAEN QKSCEPAVPF PCGRVSVSQT SKLTRAETVF 150
PDVDYVNSTE AETILDNITQ STQSFNDFTR VVGGEDAKPG QFPWQVVLNG 200
KVDAFCGGSI VNEKWIPTAA HCVETGVKIT VVAGEHNIEE TEHTEQKRNV 250
IRIIPHHNIN AAINKYNHDI ALLELDEPLV LNSYVTPICI ADKEYTNIFL 300
KFGSGYVSCW GRVFKGRSA LVLQYLRVPL VDRATCLRST KFTIYNNMFC 350
AGFHEGGRDS CQGDGSGPHV TEVEGTSFLT GIISWGEECA MKGKYGIYTK 400
VSRVYNWIKK KTKLT 415

```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 18-23 51-62 56-71 73-82 88-99 95-109
 111-124 132-289 206-222 336-350 361-389

Modified residues / Résidus modifiés / Restos modificados

E
 7-8-15-17-20-21-26-27-30-33-36-40
 4-carboxyGlu



Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
 Asn-157 Asn-167

trifarotenum


trifarotene

3''-*tert*-butyl-4'-(2-hydroxyethoxy)-4''-(pyrrolidin-1-yl)[1,1':3',1'']terphenyl-4-carboxylic acid

trifarotène

acide 3''-*tert*-butyl-4'-(2-hydroxyéthoxy)-4''-(pyrrolidin-1-yl)[1,1':3',1'']terphényl-4-carboxylique

trifaroteno

ácido 3''-*terc*-butil-4'-(2-hidroxiétoxi)-4''-(pirrolidin-1-il)[1,1':3',1'']terfenil-4-carboxílicoC₂₉H₃₃NO₄**vercirnonum**


vercirnon

4-[5-chloro-2-(4-*tert*-butylbenzenesulfonamido)benzoyl]pyridine *N*-oxide

vercirnon

4-[5-chloro-2-(4-*tert*-butylbenzènesulfonamido)benzoyl]pyridine *N*-oxide

vercirnón

N-óxido de 4-[5-cloro-2-(4-*terc*-butilbencenosulfonamido)benzoil]piridinaC₂₂H₂₁ClN₂O₄S**vintafolidum #**

vintafolide


N-(4-[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino)benzoyl)-L-γ-glutamyl-L-α-aspartyl-L-arginyl-L-α-aspartyl-L-α-aspartyl-L-cysteine disulfide with methyl (5*S*,7*R*,9*S*)-5-ethyl-9-[(3*aR*,4*R*,5*S*,5*aR*,10*bR*,13*aR*)-3*a*-ethyl-4,5-dihydroxy-8-methoxy-6-methyl-5-[(2-[(2-sulfanylethoxy)carbonyl]hydrazinyl)carbonyl]-3*a*,4,5,5*a*,6,11,12,13*a*-octahydro-1*H*-indolizino[8,1-*cd*]carbazol-9-yl]-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2*H*-3,7-methanoazacycloundecino[5,4-*b*]indol-9-carboxylate

vintafolide

N-(4-[(2-amino-4-oxo-1,4-dihydroptéridin-6-yl)méthyl]amino)benzoyl)-L-γ-glutamyl-L-α-aspartyl-L-arginyl-L-α-aspartyl-L-α-aspartyl-3-[2-[2-[(2-[(3*aR*,4*R*,5*S*,5*aR*,10*bR*,13*aR*)-3*a*-éthyl-9-[(5*S*,7*R*,9*S*)-5-éthyl-5-hydroxy-9-(méthoxycarbonyl)-1,4,5,6,7,8,9,10-octahydro-2*H*-3,7-méthanoazacycloundécino[5,4-*b*]indol-9-yl]-4,5-dihydroxy-8-méthoxy-6-méthyl-3*a*,4,5,5*a*,6,11,12,13*a*-octahydro-1*H*-indolizino[8,1-*cd*]carbazol-9-yl]carbonyl]hydrazino]carbonyl]oxy)éthyl]disulfanyl)-L-alanine

vintafolida

N-(4-[(2-amino-4-oxo-1,4-dihydropteridina-6-il)metil]amino)benzoil)-L-γ-glutamyl-L-α-aspartil-L-arginil-L-α-aspartil-L-α-aspartil-3-{2-[2-[(3a*R*,4*R*,5*S*,5a*R*,10b*R*,13a*R*)-3a-etil-9-[(5*S*,7*R*,9*S*)-5-etil-5-hidroxi-9-(metoxicarbonil)-1,4,5,6,7,8,9,10-octahidro-2*H*-3,7-metanoazacicoundecino[5,4-*b*]indol-9-il)-4,5-dihidroxi-8-metoxi-6-metil-3a,4,5,5a,6,11,12,13a-octahidro-1*H*-indolizino[8,1-*cd*]carbazol-9-il)carbonil)hidrazino]carbonil)oxi)etil]disulfanil)-L-alanina



vocimagenum amiretrorepvecum #
vocimagene amiretrorepvec

recombinant replication-competent retrovirus vector encoding a human codon optimized yeast cytosine deaminase gene, carrying three stabilizing point mutations (A23L/ V108T/I140L) and translated via an EMCV IRES (encephalomyocarditis virus internal ribosomal entry site)

vocimagène amirétrorépvec

vecteur rétroviral recombinant répliquant codant le gène de la cytosine désaminase de levure optimisé par des codons humains, comprenant trois points de mutations stabilisants (A23L/ V108T/I140L) et traduit sous le contrôle de la séquence IRES (site d'entrée interne du ribosome) du virus de l'encéphalomyocardite (EMCV)

vocimagén amiretrorepvec

vector retroviral recombinante replicante que codifica el gen de la citosina desaminasa de levadura optimizada por codones humanos, que comprende tres puntos de mutaciones estabilizadores (A23L/ V108T/I140L) y traducido bajo el control de la secuencia IRES (sitio de entrada interna del ribosoma) del virus de la encefalomiocarditis (EMCV)

vorsetuzumabum #
vorsetuzumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* CD70 (tumor necrosis factor superfamily member 7, TNFSF7, CD27LG, CD27L)], humanized monoclonal antibody; gamma1 heavy chain (1-448) [humanized VH (*Homo sapiens* IGHV1-2*02 (86.70%) -(IGHD)-IGHJ6*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*01 (119-448)], (221-218')-disulfide with kappa light chain (1'-218') [humanized V-KAPPA (*Homo sapiens* IGKV4-1*01 (79.20%) -IGKJ1*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01 (112'-218')]; (227-227'':230-230'')-bisdisulfide dimer

vorsetuzumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* CD70 (membre 7 de la superfamille du facteur de nécrose tumorale (TNF), TNFSF7, CD27LG, CD27L)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-448) [VH humanisé (*Homo sapiens* IGHV1-2*02 (86.70%) -(IGHD)-IGHJ6*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*01 (119-448)], (221-218'-disulfure avec la chaîne légère kappa (1'-218') [V-KAPPA humanisé (*Homo sapiens* IGKV4-1*01 (79.20%) -IGKJ1*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01 (112'-218')]; dimère (227-227'':230-230'')-bisdisulfure

vorsetuzumab

immunoglobulina G1-kappa, anti-[CD70 de *Homo sapiens* (miembro 7 de la superfamilia del factor de necrosis tumoral (TNF), TNFSF7, CD27LG, CD27L)], anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-448) [VH humanizado (*Homo sapiens* IGHV1-2*02 (86.70%) -(IGHD)-IGHJ6*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*01 (119-448)], (221-218'-disulfuro con la cadena ligera kappa (1'-218') [V-KAPPA humanizada (*Homo sapiens* IGKV4-1*01 (79.20%) -IGKJ1*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01 (112'-218')]; dímero (227-227'':230-230'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGASVKV SCKASGYTFT NYGMNWRQA PGQGLKWMGW 50
INTYTGEPY ADAPKGRVTM TRDTSISTAY MELSRRLRSD TAVVYCARY 100
GDYGMIDYWGQ GTTIVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200
CNVNHKPSNT KVDKKVEPKS CDKTHCTCPPC PAPELLGGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGEVHNHAKT KPREEQYNST 300
YRVVSVLTIVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350
LTPFSRDELT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTPFPVLD 400
SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK 448
```

Light chain / Chaîne légère / Cadena ligera

```
DIVMTQSPDS LAVSLGERAT INCRASKSVS TSGYSFMHWY QQKPGQPPKL 50
LIYLASNLES GVPDRFSGSG SGTDFTLTIS SLQAEDVAVY YCQHSREVW 100
TFGQGTKEVI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFPYPREAKV 150
QWKVDNALQS GNSQESVTEQ DSKDSTYSL STLTLSKADY EKHKVYACEV 200
THQGLSSPVT KSFNRGEC 218
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H 22-96 145-201 262-322 368-426
        22"-96" 145"-201" 262"-322" 368"-426"
Intra-L 23'-92' 138'-198'
        23'''-92''' 138'''-198'''
Inter-H-L 221-218' 221"-218'"
Inter-H-H 227-227" 230-230"
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
298, 298"

vorsetuzumabum mafodotinum #
vorsetuzumab mafodotin

immunoglobulin G1-kappa auristatin F conjugate, anti-[*Homo sapiens* CD70 (tumor necrosis factor superfamily member 7, TNFSF7, CD27LG, CD27L)], humanized monoclonal antibody conjugated to auristatin F; gamma1 heavy chain (1-448) [humanized VH (*Homo sapiens* IGHV1-2*02 (86.70%) -(IGHD)-IGHJ6*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*01 (119-448)], (221-218')-disulfide (if not conjugated) with kappa light chain (1'-218') [humanized V-KAPPA (*Homo sapiens* IGKV4-1*01 (79.20%) -IGKJ1*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01 (112'-218')]; (227-227'':230-230'')-bisdisulfide dimer; conjugated, on an average of 3 to 5 cysteinyl, to monomethylauristatin F (MMAF), via a noncleavable maleimidocaproyl (mc) linker
For the *mafodotin* part, please refer to the document "*INN for pharmaceutical substances: Names for radicals, groups and others*".

vorsétuzumab mafodotine

immunoglobuline G1-kappa conjuguée à l'auristatine F, anti-[*Homo sapiens* CD70 (membre 7 de la superfamille du TNF, TNFSF7, CD27LG, CD27L)], anticorps monoclonal humanisé conjugué à l'auristatine F;
chaîne lourde gamma1 (1-448) [VH humanisé (*Homo sapiens* IGHV1-2*02 (86.70%) -(IGHD)-IGHJ6*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*01 (119-448)], (221-218'-disulfure (si non conjugué) avec la chaîne légère kappa (1'-218') [V-KAPPA humanisé (*Homo sapiens* IGKV4-1*01 (79.20%) -IGKJ1*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01 (112'-218')]; dimère (227-227":230-230")-bisdisulfure; conjugué, sur 3 à 5 cystéinyl en moyenne, au monométhylauristatine F (MMAF), via un linker maléimidocaproyl (mc) non clivable
Pour la partie *mafodotine*, veuillez-vous référer au document "*INN for pharmaceutical substances: Names for radicals, groups and others*".

vorsetuzumab mafodotina

immunoglobulina G1-kappa conjugada con auristatina F, anti-[CD70 de *Homo sapiens* (miembro 7 de la superfamilia del TNF, TNFSF7, CD27LG, CD27L)], anticuerpo monoclonal humanizado conjugado con la auristatina F;
cadena pesada gamma1 (1-448) [VH humanizado (*Homo sapiens* IGHV1-2*02 (86.70%) -(IGHD)-IGHJ6*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*01 (119-448)], (221-218'-disulfuro (si no está conjugado) con la cadena ligera kappa (1'-218') [V-KAPPA humanizado (*Homo sapiens* IGKV4-1*01 (79.20%) -IGKJ1*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01 (112'-218')]; dímero (227-227":230-230")-bisdisulfuro; conjugado en 3 -5 restos cisteinil, por término medio, con monometilauristatina F (MMAF), mediante un enlace maleimidocaproyl (mc) no escindible
Para la fracción *mafodotina*, se pueden dirigir al documento "*INN for pharmaceutical substances: Names for radicals, groups and others*".

Heavy chain / Chaîne lourde / Cadena pesada

QVQLVQSGAE	VKKPGASVKV	SCKASGYTFT	NYGMNWRQA	PGQGLKWMGW	50
INTYTGEPY	ADAFKGRVTM	TRDTSISTAY	MELSLRLSDD	TAVYYCARDY	100
GDYGMIDYWGQ	GTITVTSSAS	TKGPSVFPLA	PSSKSTSGGT	AALGCLVKDY	150
FPEPVTSWN	SGALTSGVHT	FPAVLQSSGL	YSLSSVVTVP	SSSLGTQTYI	200
CNVNHKPSNT	KVDKKEPKS	CDKTHCTPFC	PAPELLGGPS	VFLFPPKPKD	250
TLMISRTPEV	TCVVVDVSHE	DPEVKFNWYV	DGVEVHNAKT	KPREEQYNST	300
YRVVSVLTIVL	HQDNLNGKEY	KCKVSNKALP	APIEKTISKA	KGQPREPQVY	350
TLPPSRDEL	KNQVSLTCLV	KGFYPSDIAV	EWESNGQPEN	NYKTTTPVLD	400
SDGSFFLYSK	LTVDKSRWQQ	GNVFSCSVMH	EALHNHYTQK	SLSLSPGK	448

Light chain / Chaîne légère / Cadena ligera

DIVMTQSPDS	LAVSLGERAT	INCRASKSVS	TSGYSFMHWY	QOKPGQPPKL	50
LIYLASNL	GVPDRFSGSG	SGTDFTLTIS	SLQAEDVAVY	YCQHSREVPW	100
TFGQGTKVEI	KRTVAAPSVF	IFPPSDEQLK	SGTASVVCCL	NNFYPREAKV	150
QWKVDNALQS	GNSQESVTEQ	DSKDSSTYLS	STLTLSKADY	EKHKPYACEV	200
THQGLSPVT	KSFNRGEC				218

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H	22-96	145-201	262-322	368-426
	22"-96"	145"-201"	262"-322"	368"-426"
Intra-L	23"-92"	138"-198"		
	23"-92"	138"-198"		
Inter-H-L*	221-218'	221"-218"		
Inter-H-H *	227-227"	230-230"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
298, 298"

*Two or three of the inter-chain disulfide bridges are not present, the antibody being conjugated to an average of 3 to 5 drug linkers each via a thioether bond.

* Deux ou trois des ponts disulfure ne sont pas présents, l'anticorps étant conjugué à une moyenne de 3 à 5 linker-principe actif chacun via une liaison thioéther.

* Faltan dos o tres puentes disulfuro inter-catenarios por estar el anticuerpo conjugado, con sendos enlaces tioéter, a una media de 3 a 5 conectores de principio activo

zoptarelinum doxorubicinum

zoptarelin doxorubicin


[6-D-lysine]human gonadoliberein-1 (LHRH) and doxorubicin covalently linked together with glutaric acid:
5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-*N*⁶-[5-(2-((2*S*,4*S*)-4-[(3-amino-2,3,6-trideoxy- α -L-*lyxo*-hexopyranosyl)oxy]-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-2-yl)-2-oxoethoxy)-5-oxopentanoyl]-D-lysine-L-leucyl-L-arginyl-L-prolylglycinamide

zoptaréline doxorubicine

[6-D-lysine]gonadolibérine-1 humaine (LHRH) et doxorubicine liées de façon covalente par l'acide glutarique:
5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-séryl-L-tyrosyl-*N*⁶-[5-(2-((2*S*,4*S*)-4-[(3-amino-2,3,6-tridésoxy- α -L-*lyxo*-hexopyranosyl)oxy]-2,5,12-trihydroxy-7-méthoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotétracén-2-yl)-2-oxoéthoxy)-5-oxopentanoyl]-D-lysine-L-leucyl-L-arginyl-L-prolylglycinamide

zoptarelina doxorubicina

[6-D-lisina]gonadolibarina-1 humana (LHRH) y doxorubicina unidas covalentemente mediante ácido glutárico:
5-oxo-L-prolil-L-histidil-L-triptofil-L-seril-L-tirosil-*N*⁶-[5-(2-((2*S*,4*S*)-4-[(3-amino-2,3,6-tridesoxi- α -L-*lyxo*-hexopiranosil)oxi]-2,5,12-trihidroxi-7-metoxi-6,11-dioxo-1,2,3,4,6,11-hexahidrotetracén-2-il)-2-oxoetoxi)-5-oxopentanoil]-D-lisina-L-leucil-L-arginil-L-prolilglicinamida



* <http://www.who.int/medicines/services/inn/publication/en/index.html>

Electronic structure available on Mednet: <http://mednet.who.int/>

Structure électronique disponible sur Mednet: <http://mednet.who.int/>

Estructura electrónica disponible en Mednet: <http://mednet.who.int/>

**AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES**

Recommended International Non Proprietary Names (Rec. INN): List 61
Dénominations communes internationales recommandées (DCI Rec.): Liste 61
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 61
(WHO Drug Information, Vol. 23, No. 1, 2009)

p. 53 **bevasiranibum**

bevasiranib
bévasiranib
bevasiranib

replace the description, molecular formula and the structure by the following ones
remplacer la description, la formule moléculaire et la structure par les suivants
sustitúyase la descripción, la fórmula molecular y la estructura por los siguientes

siRNA inhibitor of Vascular Endothelial Growth Factor (VEGF) production;
 duplex of adenylyl-(3'→5')-cytidyl-(3'→5')-cytidyl-(3'→5')-uridylyl-(3'→5')-cytidyl-(3'→5')-adenylyl-(3'→5')-cytidyl-(3'→5')-cytidyl-(3'→5')-adenylyl-(3'→5')-adenylyl-(3'→5')-guanylyl-(3'→5')-guanylyl-(3'→5')-cytidyl-(3'→5')-cytidyl-(3'→5')-adenylyl-(3'→5')-guanylyl-(3'→5')-cytidyl-(3'→5')-adenylyl-(3'→5')-cytidyl-(3'→5')-thymidyl-(3'→5')-thymidine and thymidyl-(5'→3')-thymidyl-(5'→3')-uridylyl-(5'→3')-guanylyl-(5'→3')-guanylyl-(5'→3')-adenylyl-(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-uridylyl-(5'→3')-cytidyl-(5'→3')-cytidyl-(5'→3')-guanylyl-(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-cytidyl-(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-guanosine

petit ARN interférant (siRNA) inhibiteur de la production du facteur de croissance de l'endothélium vasculaire (VEGF) ;

duplex d'adénylyl-(3'→5')-cytidyl-(3'→5')-cytidyl-(3'→5')-uridylyl-(3'→5')-cytidyl-(3'→5')-adénylyl-(3'→5')-cytidyl-(3'→5')-cytidyl-(3'→5')-adénylyl-(3'→5')-adénylyl-(3'→5')-guanylyl-(3'→5')-guanylyl-(3'→5')-cytidyl-(3'→5')-cytidyl-(3'→5')-adénylyl-(3'→5')-guanylyl-(3'→5')-cytidyl-(3'→5')-adénylyl-(3'→5')-cytidyl-(3'→5')-thymidyl-(3'→5')-thymidine et de thymidyl-(5'→3')-thymidyl-(5'→3')-uridylyl-(5'→3')-guanylyl-(5'→3')-guanylyl-(5'→3')-adénylyl-(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-uridylyl-(5'→3')-cytidyl-(5'→3')-cytidyl-(5'→3')-guanylyl-(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-cytidyl-(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-guanosine

ARN pequeño de interferencia (siRNA) inhibidor de la producción del factor de crecimiento endotelial vascular (VEGF);

dúplex de adenilil-(3'→5')-citidilil-(3'→5')-citidilil-(3'→5')-uridilil-(3'→5')-citidilil-(3'→5')-adenilil-(3'→5')-citidilil-(3'→5')-citidilil-(3'→5')-adenilil-(3'→5')-adenilil-(3'→5')-guanilil-(3'→5')-guanilil-(3'→5')-citidilil-(3'→5')-citidilil-(3'→5')-adenilil-(3'→5')-guanilil-(3'→5')-citidilil-(3'→5')-adenilil-(3'→5')-citidilil-(3'→5')-timidilil-(3'→5')-timidina y timidilil-(5'→3')-timidilil-(5'→3')-uridilil-(5'→3')-guanilil-(5'→3')-guanilil-(5'→3')-adenilil-(5'→3')-guanilil-(5'→3')-uridilil-(5'→3')-guanilil-(5'→3')-guanilil-(5'→3')-uridilil-(5'→3')-uridilil-(5'→3')-citidilil-(5'→3')-citidilil-(5'→3')-guanilil-(5'→3')-guanilil-(5'→3')-uridilil-(5'→3')-citidilil-(5'→3')-guanilil-(5'→3')-uridilil-(5'→3')-guanosina

$C_{401}H_{503}N_{153}O_{290}P_{40}$

(3'→5') A-C-C-U-C-A-C-C-A-A-G-G-C-C-A-G-C-A-C-dT-dT
 (5'→3') dT-dT-U-G-G-A-G-U-G-G-U-U-C-C-G-G-U-C-G-U-G

Recommended International Nonproprietary Names (Rec. INN): List 63
Dénominations communes internationales recommandées (DCI Rec.): Liste 63
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 63
(WHO Drug Information, Vol. 24, No. 1, 2010)

p. 70	ridaforolimusum	
	ridaforolimus	<i>replace the chemical name by the following one</i>
	ridaforolimus	<i>sustitúyase el nombre químico por el siguiente</i>
		(1 <i>R</i> ,2 <i>R</i> ,4 <i>S</i>)-4-[(2 <i>R</i>)-2- {(3 <i>S</i> ,6 <i>R</i> ,7 <i>E</i> ,9 <i>R</i> ,10 <i>R</i> ,12 <i>R</i> ,14 <i>S</i> ,15 <i>E</i> ,17 <i>E</i> ,19 <i>E</i> ,21 <i>S</i> ,23 <i>S</i> ,26 <i>R</i> ,27 <i>R</i> ,34 <i>aS</i>)-9,27-dihydroxy- 10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-1,5,11,28,29-penta-oxo- 1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a- tetracosahydro-3 <i>H</i> -23,27-epoxy-2,1- <i>c</i>][1,4]oxaazacyclohentacontin- 3-yl}propyl]-2-methoxycyclohexyl dimethylphosphinate
		dimetilfosfinato de (1 <i>R</i> ,2 <i>R</i> ,4 <i>S</i>)-4-[(2 <i>R</i>)-2- {(3 <i>S</i> ,6 <i>R</i> ,7 <i>E</i> ,9 <i>R</i> ,10 <i>R</i> ,12 <i>R</i> ,14 <i>S</i> ,15 <i>E</i> ,17 <i>E</i> ,19 <i>E</i> ,21 <i>S</i> ,23 <i>S</i> ,26 <i>R</i> ,27 <i>R</i> ,34 <i>aS</i>)-9,27-dihidroxi- 10,21-dimetoxi-6,8,12,14,20,26-hexametil-1,5,11,28,29-penta-oxo- 1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a- tetracosahidro-3 <i>H</i> -23,27-epoxipirido[2,1- <i>c</i>][1,4]oxaazaciclohentriacontin-3-il}propil]- 2-metoxiciclohexilo

Recommended International Non Proprietary Names (Rec. INN): List 65
Dénominations communes internationales recommandées (DCI Rec.): Liste 65
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 65
(WHO Drug Information, Vol. 25, No. 1, 2011)

p. 76	obinutuzumabum	
	obinutuzumab	<i>replace the structure by the following one</i>
	obinutuzumab	<i>remplacer la structure par la suivante</i>
	obinutuzumab	<i>sustitúyase la estructura por la siguiente</i>
		Heavy chain / Chaîne lourde / Cadena pesada
		QVQLVQSGAE VKKPGSSVKV SCKASGYAFS YSWINWVRQA PGQGLEWMGR 50
		IFPGDGDYD NGKFKGRVTI TADKSTSTAY MELSSLRSED TAVYYCARNV 100
		FDGYWLVYWG QGTLTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
		YFPEPVTISW NSGALTSGVH TFFPAVLQSSG LYSLSVVTV PSSSLGTQTY 200
		ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
		DTLMISRTP E VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
		TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
		YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTTPVL 400
		DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK 449
		Light chain / Chaîne légère / Cadena ligera
		DIVMTQTPLS LPVTPGEPAS ISCRSSKSL HSGITYLYW YLQKPGQSPQ 50 '
		LLIYQMSNLV SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCAQNLELP 100 '
		YTFGGGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVCL LNNFYPPREK 150 '
		VQWKVDNALQ SGNSQESVTE QDSKDYSTSL SSTLTLSKAD YEKHKVYACE 200 '
		VTHQGLSPV TKSFNREGC 219 '
		Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
		22-96 22"-96" 23'-93' 23"-93" 139'-199' 139"-199" 146-202 146"-202"
		219'-222 219"-222" 228-228" 231-231" 263-323 263"-323" 369-427 369"-427"
		Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
		H CH2 N84.4
		299, 299" (enriched in bisected non-fucosylated oligosaccharides)

p. 81 **peginesatidum**

peginesatide

péginésatide


peginesatida

*replace the description and the structure by the following ones**remplacer la description et la structure par les suivants**sustitúyase la descripción y la estructura por los siguientes*

pegylated erythropoietin receptor agonist;
 $N^{6,21}, N^{6,21'} - \{[(N^2, N^6 - \text{bis}[\{(\omega\text{-methoxypoly(oxyethylene)})\text{carbonyl}]\text{-DL-lysyl-}\beta\text{-alanyl})\text{imino}] \text{bis}(\text{methylenecarbonyl})\} \text{bis}[\text{acetylglycylglycyl-L-leucyl-L-tyrosyl-L-alanyl-L-cysteinyl-L-histidyl-L-methionylglycyl-L-prolyl-L-isoleucyl-L-threonyl-3-(naphthalen-1-yl)-L-alanyl-L-valyl-L-cysteinyl-L-glutaminy-L-prolyl-L-leucyl-L-arginyl-N-methylglycyl-L-lysine}] (6 \rightarrow 15:6' \rightarrow 15')\text{-bisdisulfide cyclic}$

agoniste du récepteur de l'érythropoïétine, pégylé ;
 $(6 \rightarrow 15:6' \rightarrow 15')\text{-bisdisulfure cyclique du } N^{6,21}, N^{6,21'} - \{[(N^2, N^6 - \text{bis}[\{(\omega\text{-méthoxypoly(oxyéthylène)})\text{carbonyl}]\text{-DL-lysyl-}\beta\text{-alanyl})\text{imino}] \text{bis}(\text{méthylènecarbonyl})\} \text{bis}[\text{acétylglycylglycyl-L-leucyl-L-tyrosyl-L-alanyl-L-cystéinyl-L-histidyl-L-méthionylglycyl-L-prolyl-L-isoleucyl-L-thréonyl-3-(naphtalén-1-yl)-L-alanyl-L-valyl-L-cystéinyl-L-glutaminy-L-prolyl-L-leucyl-L-arginyl-N-méthylglycyl-L-lysine}]$

agonista del receptor de la eritropoyetina, pegilado;
 $(6 \rightarrow 15:6' \rightarrow 15')\text{-bisdisulfuro cíclico del } N^{6,21}, N^{6,21'} - \{[(N^2, N^6 - \text{bis}[\{(\omega\text{-metoxipoly(oxietileno)})\text{carbonyl}]\text{-DL-lisil-}\beta\text{-alanil})\text{imino}] \text{bis}(\text{metilenocarbonyl})\} \text{bis}[\text{acetilglicilglicil-L-leucil-L-tirosil-L-alanil-L-cisteinil-L-histidil-L-metionilglicil-L-prolil-L-isoleucil-L-treonil-3-(naftalen-1-il)-L-alanil-L-valil-L-cisteinil-L-glutaminil-L-prolil-L-leucil-L-arginil-N-metilglicil-L-lisina}]$



Recommended International Non Proprietary Names (Rec. INN): List 66
Dénominations communes internationales recommandées (DCI Rec.): Liste 66
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 66
(WHO Drug Information, Vol. 25, No. 3, 2011)

p. 332 **turoctocogum alfa #**

turoctocog alfa *replace the description, the molecular formula and the structure by the following*
 turoctocog alfa *remplacer la description, la formule moléculaire et la structure par les suivantes*
 turoctocog alfa *sustitúyase la descripción, la fórmula molecular y la estructura por las siguientes*

human coagulation factor VIII-(1-750)-(1638-1648)-peptide compound with human coagulation factor VIIIa light chain, glycosylated
 des-(751-1637)-human coagulation factor VIII-(1-1648)-peptide containing 92 kDa factor VIIIa heavy chain compound with human coagulation factor VIIIa light chain glycosylated (glycoform alfa produced in CHO cells)

facteur VIII de coagulation humain-(1-750)-(1638-1648)-peptide associé à la chaîne légère du facteur VIIIa de coagulation humain glycosylés
 dès-(751-1637)-facteur VIII de coagulation humain-(1-1648)-peptide contenant la chaîne lourde de 92 kDa du facteur VIIIa associé à la chaîne légère du facteur VIIIa de coagulation humain glycosylés (glycoforme alfa produit par des cellules CHO)

factor VIII de coagulación humano-(1-750)-(1648)-péptido asociado a la cadena ligera del factor VIIIa de coagulación humano, glicosilados
 des-(751-1637)-factor VIII de coagulación humano-(1-1648)-péptido que contiene la cadena pesada de 92kDa del factor VIIIa asociada a la cadena ligera del factor VIIIa de coagulación humano glicosilados (glicofoma alfa producida por células CHO)

C₇₄₈₀H₁₁₃₈₁N₁₉₉₉O₂₁₉₅S₆₈ (peptide)

Heavy chain / Chaîne lourde / Cadena pesada

ATRRYYLGAV ELSWDYMQSD LGELPVDARF PPRVPKSPFF NTSVVYKKTLL 50
 FVEFTDHLFN IAKPRPPWMG LLGPTIQAEV YDTVVITLKN MASHPVSLHA 100
 VGVSYWKASE GAEDDDQTSQ REKEDDKVFP GGSHTYVWQV LKENGPMASD 150
 PLCLTYSYLS HVDLVKDLNS GLIGALLVCR EGS LAKEKTO TLHKFILLFA 200
 VFDEGKSWHS ETKNSLMQDR DAASARAWPK MHTVNGYVNR SLPLGLIGCHR 250
 KSVYWHVIGM GTTPEVHSIF LEGHTFLVRN HRQASLEISP ITFLTAQTLL 300
 MDLGQFLLCF HISSHQHDMG EAYVKVDSCE EPQLRMKN EEAEDYDDDL 350
 TDSEMDVVRP DDDNSPSFIQ IRSAKAKHPK TWVHYIAAEE EDWDYAPLVL 400
 APDRSRYKSO YLNNGPQRIG RYKVKVRFMA YDTEFTKTR EIQHESGILG 450
 PLYGEVCDT LLIIIFKNQAS RPYNIYPHGI TDVRPLYSRP LPKGVKHLKD 500
 FPILPGEIFK YKWTVTVEDG PTKSDPRCLT RYSSSFVNME RDLASGLIGP 550
 LLICYKESVD QRGNQIMSDK RNVILFVSVD ENRSWYLTEN IQRFPLNPAG 600
 VQLEDPEFQA SNIMHSINGY VFDLQLSVC LHEVAYWYIL SIGAQTDFLS 650
 VFFSGYTFKH KMVYEDTLTL PFFSGETVFM SMENPGLWIL GCHNSDFRNR 700
 GMTALLKVSS CDKNTGDYIE DSYEDISAYL LSKNNAIEPR SFSQNSRHFS 750
 QNPVVKRRHQ R 761

Light chain / Chaîne légère / Cadena ligera

TRITLQSDQE EIDYDDTISV EMKKEDFDIY DEDENQSPRS FQKKTRHYFI 1650
 AAVRLWDYG MSSSPHVLNR RAQSGSVQPF KKVVFQEFDT GSFTQPLYRG 1750
 ELNEHLGLLG PYIRAEVEDN IMVTFRNQAS RPYSFYSSLI SYEEDQRQGA 1800
 EPRKNFVKPN ETKTYFWKVQ HHMAPTKDEF DCKAWAYFSD VDLEKDVHSG 1850
 LIGPLLCHT NTLNPAHGRQ VTVQEFALFF TIFDETSWY FTENMERNCR 1900
 APCNIQMEDP TFKENYRFHA INGYIMDTLP GLVMAQDQRI RWYLLSMGSN 1950
 ENIHSHFSG HVFTVRKKEE YKMALYNLYP GVFTVEMLP SKAGIWRVEC 2000
 LIGELHAGM STLFLVYSNK CQTPLGMASG HIRDFQITAS GQYQGWAPKL 2050
 ARLHYSGSIN AWSTKEPFSW IKVDLLAPMI IHGKTQGAR QKFSSLYISQ 2100
 FIIMYSLDGK KWQTYRGNST GTLMVFFGNV DSSGIKHNIF NPPIIARYIR 2150
 LHPTHYSIRS TLRMELMGCD LNSCSMPLGM ESKAISDAQI TASSYFTNMF 2200
 ATWSPSKARL HLQGRSNAWR PQVNNPKEWL QVDFQKTMKV TGVTTQGVKS 2250
 LLTSMYKKEF LISSSQDGHQ WTLFFQNGKV KVFQGNQDSF TFPVNTSLDPP 2300
 LLTRYLRIHP QSWVHQIALR MEVLGCEAQD LY 2332

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 153-179 248-329 528-554 630-711 1832-1858 1899-1903 2021-2169 2174-2326

Sulfated residues (Y) / Résidus sulfatés (Y) / Restos sulfatados (Y)

Tyr-346 Tyr-718 Tyr-719 Tyr-723 Tyr-1664 Tyr-1680

Glycosylation sites (N_S) / Sites de glycosylation (N_S) / Posiciones de glicosilación (N_S)

Asn-41 Asn-239 Ser-750 Asn-1810 Asn-2118

Recommended International Non Proprietary Names (Rec. INN): List 67
Dénominations communes internationales recommandées (DCI Rec.): Liste 67
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 67
(WHO Drug Information, Vol. 26, No. 1, 2012)

p. 72	mericitabinum	
	mericitabine	<i>replace the chemical name by the following one</i>
	mericitabina	<i>sustitúyase el nombre químico por el siguiente</i>
		(2' <i>R</i>)-2'-deoxy-2'-fluoro-2'-methyl-3',5'-bis-O-(2-methylpropanoyl)cytidine
		(2' <i>R</i>)-2'-desoxi-2'-fluoro-2'-metil-3',5'-bis-O-(2-metilpropanoil)citidina

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en las listas de DCI propuestas.